Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

You’ve supercharged your research process with ACS and Mendeley!

STEP 1:
Click to create an ACS ID

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

MENDELEY PAIRING EXPIRED
Your Mendeley pairing has expired. Please reconnect
ACS Publications. Most Trusted. Most Cited. Most Read
Discovery of a Neuroprotective Chemical, (S)-N-(3-(3,6-Dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine [(−)-P7C3-S243], with Improved Druglike Properties
More

OR SEARCH CITATIONS

My Activity
Publications

Figure 1Loading Img
Download Hi-Res ImageDownload to MS-PowerPointCite This:J. Med. Chem. 2014, 57, 9, 3746-3754
  • Open Access
Article

Discovery of a Neuroprotective Chemical, (S)-N-(3-(3,6-Dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine [(−)-P7C3-S243], with Improved Druglike Properties
Click to copy article linkArticle link copied!

View Author Information
† Departments of †Biochemistry and ‡Neuroscience, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9038, United States
§ Departments of Psychiatry, Neurology, and Veterans Affairs, University of Iowa Carver College of Medicine, 200 Hawkins Avenue, Iowa City, Iowa 52242, United States
∥ National Institute of Mental Health Psychoactive Drug Screening Program, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
*E-mail: [email protected] (A.A.P.).
*E-mail: [email protected] (J.M.R.).
Open PDFSupporting Information (2)

Journal of Medicinal Chemistry

Cite this: J. Med. Chem. 2014, 57, 9, 3746–3754
Click to copy citationCitation copied!
https://doi.org/10.1021/jm401919s
Published April 3, 2014

Copyright © 2014 American Chemical Society. This publication is licensed under these Terms of Use.

Request reuse permissions

Abstract

Click to copy section linkSection link copied!
High Resolution Image
Download MS PowerPoint Slide

(−)-P7C3-S243 is a neuroprotective aminopropyl carbazole with improved druglike properties compared with previously reported compounds in the P7C3 class. It protects developing neurons in a mouse model of hippocampal neurogenesis and protects mature neurons within the substantia nigra in a mouse model of Parkinson’s disease. A short, enantioselective synthesis provides the neuroprotective agent in optically pure form. It is nontoxic, orally bioavailable, metabolically stable, and able to cross the blood–brain barrier. As such, it represents a valuable lead compound for the development of drugs to treat neurodegenerative diseases and traumatic brain injury.

Copyright © 2014 American Chemical Society

Subjects

what are subjects

Neurodegenerative diseases currently affect millions of people worldwide, and the incidence of disease is rapidly increasing as the aging population expands. The magnitude and trend of this problem places a growing human and financial strain on healthcare systems, which is exacerbated by the absence of effective treatments for many of the most common afflictions. (1) Neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD), traumatic brain injury (TBI), and normal age-related cognitive decline feature, by definition, neuronal cell death. Accordingly, we have searched for small molecules that could prevent the death of neurons in a variety of in vivo contexts. We hypothesize that such neuroprotective agents could possess general utility for treating disorders associated with neuron cell death.
Rather than focusing on predefined molecular targets thought to be related to specific neurodegenerative diseases, we have searched for small molecules with in vivo neuroprotective properties. In 2010 we reported the results of an unbiased in vivo screen designed to identify such agents. This assay involved administration of compounds concurrent with exposure to the thymidine analogue bromodeoxyuridine (BrdU), which marked newly born neurons through incorporation into newly synthesized DNA. The neuroprotective efficacy of compounds was gauged by evaluating their protective effect on newborn neurons within the hippocampus over a 1 week period. Under the assay conditions, around 40% of newborn neural precursor cells in the hippocampus of untreated or vehicle-treated mice underwent apoptotic cell death within 1 week of their birth. Our screen revealed an aminopropyl carbazole, which we named P7C3 (1), (2) that approximately doubled the number of surviving newborn hippocampal cells at this time point. Additional experiments demonstrated that 1 and derivatives thereof increased the number of new neurons by blocking apoptotic cell death rather than by increasing neural stem cell proliferation. Subsequent chemical optimization yielded P7C3-A20 (2), (3) a derivative with improved potency and toxicity profile that is available on a large scale. (4) Recently, we and others have shown that the P7C3 class of compounds are broadly protective of mature neurons, with potent efficacy in multiple models of neurodegenerative disease. For instance, we discovered that 1 and 2 protect neurons in the substantia nigra (SNc) in a mouse model of PD involving the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). (5) Similarly, we found that they minimize motor neuron cell death in the spinal cord of G93A SOD1 transgenic mice, a common model of ALS. (6) More recently, 2 was found to protect rat cerebral cortical neurons in the moderate fluid percussion model of TBI and to exert antidepressant effects by increasing hippocampal neurogenesis. (7, 8) Finally, 1 demonstrated neuroprotective effects in a rat model of age-related cognitive decline (2) and a zebrafish model of retinal degeneration. (9) While the antidepressant activity of 1 and 2 is correlated with protection of immature neurons, in all other cases, 1 and/or 2 protected mature neurons from cell death. Moreover, in cases where neuron death was associated with behavioral or learning deficits, neuroprotective efficacy was reflected in an improvement in motor function and/or learning and memory.
While 2 is active, orally available, brain-penetrant, and nontoxic, even at doses in excess of the minimally efficacious dose, we recognized the opportunity to design a molecule with improved druglike properties. In particular, we sought to replace the aniline moiety of 2 with an alternative heterocycle, increase the polarity of the compound, and synthesize the drug lead as a single enantiomer. Few marketed drugs contain aniline moieties, and most chiral drugs are produced in optically active form. Here we describe the discovery and evaluation of (−)-P7C3-S243 (15), a neuroprotective agent with improved physicochemical properties. It appears to be nontoxic and more efficacious than 1 and 2 in animal models of PD. It therefore represents an optimized neuroprotective agent emerging from the P7C3 class of compounds.

Results

Click to copy section linkSection link copied!
Prior and ongoing work in our groups indicates that the P7C3 class of compounds exert their neuroprotective effects by stabilizing mitrochondria against the depolarization events that are known to trigger apoptosis. (2) Nonetheless, our most robust assay involves monitoring neuroprotection of newborn hippocampal neurons in mice because this assay gives a simultaneous readout of efficacy, acute toxicity, and cell permeability. For this reason, all analogues of 1 were evaluated initially by infusing them directly into the left lateral ventricle of environmentally deprived (10) live mice using a subcutaneously implanted osmotic minipump. Compounds were delivered intracerebroventricularly (ICV) over a 7 day period at a concentration of 10 μM (12 μL/day). (11) Mice were additionally dosed intraperitoneally (IP) daily with BrdU (50 mg/kg) to mark newly born hippocampal neural precursor cells. At the end of the 1 week dosing, animals were sacrificed and transcardially perfused. Brain slices were stained with antibodies to BrdU, and the number of surviving neural precursor cells was quantified by counting the number of BrdU+ cells in the hippocampal dentate gyrus. To avoid complications arising from the surgical implantation of the pump, we quantified neurogenesis in the hemisphere opposite to compound infusion. Finally, to obtain consistent data across many animals, the number of BrdU+ cells was normalized to the volume of the dentate gyrus.
Our initial objective was to replace the aniline ring with a heterocyclic ring. Previous studies had shown that the N-phenyl ring of 1 could be replaced with a 2-pyridyl group (giving 3), but not a 3- or 4-pyridyl group, while maintaining activity in the in vivo hippocampal neuroprotection assay. (3) Moreover, we had discovered that fluorination of the central methylene and substitution of the N-aryl ring improved the activity, but neither change alone had substantial impact. For example, 4 (i.e., methoxy-1) and 5 (i.e., fluoro-1) showed similar activity as 1. However, fluorinating the anisidine congener 4 to provide 2 substantially improved the activity in the hippocampal neuroprotection assay. In this context, we targeted 15, a fluorinated compound containing a methoxy-substituted 2-aminopyridine. Following the approach we described for the large-scale synthesis of 2, (4) terminal epoxide 7 was opened with 4-nitrobenzenesulfonyl (4-nosyl, 4-Ns)-protected 2-methoxy-6-aminopyridine (Scheme 1). Surprisingly, when the resultant amino alcohol 8 was subjected to fluorination conditions with MorphoDast, HPLC/MS and 1H NMR analyses indicated the formal loss of methanol. We speculated that the pyridine nitrogen displaced an activated alcohol and the cyclized pyridinium salt (not shown) was demethylated to yield aminopyridone 9.

Scheme 1

High Resolution Image
Download MS PowerPoint Slide
We next considered an approach involving amination of a primary amine. To this end, epoxide 7 was opened with sodium azide. The resulting secondary alcohol 10 was fluorinated to provide azido fluoride 11, and the azide was reduced with triphenylphosphine to yield fluoroamine 12. Reaction of this amine with iodopyridine 13 (12) in the presence of CuI and diketone ligand 14 provided the desired analogue 15 in high yield on a multigram scale. (13) Alternative conditions featuring Pd catalysts or lacking the diketone ligand provided less than 20% yield of the intended product. In a similar manner, amino alcohol 16 was arylated to provide 17, the hydroxy congener of 15. Amino alcohol 16 proved to be much less reactive than fluoroamine 12, resulting in incomplete conversion. Moreover, in this case adding the diketone ligand improved the yield by only around 10%, suggesting that the amino alcohol itself can serve as a ligand for Cu. (14)
As described above, compounds were administered to mice ICV over a 1 week period concurrent with dosing of BrdU IP. Figure 1 shows that aminopyridine 15 approximately doubled the number of surviving newborn hippocampal neurons over this time period and displayed an activity superior to that of 1 and comparable to that of 2. Several of the synthetic intermediates also displayed neuroprotective activity in this assay. While azide 11 was inactive under the conditions of this experiment, the primary amines 12 and 16 as well as the N-pyridyl amino alcohol 17 showed an increase in the number of BrdU+ cells compared with vehicle. However, these intermediates were less potent than 15 and even slightly less active than our initial hit 1. We originally adopted intracerebroventricular delivery to avoid complications related to brain penetration. Nonetheless, ICV is clearly not an ideal method of dosing. Fortunately, the optimized lead 15 showed a smooth dose–response curve upon intraperitoneal (IP) administration. It was active at a dose of 1 mg kg–1 day–1 and reached its ceiling of efficacy at 10 mg kg–1 day–1, results which parallel those found in the MPTP model of Parkinson’s disease (see below). Control experiments demonstrated that the increase in BrdU+ neurons within the hippocampus was due to neuroprotection rather than increased neural stem cell proliferation (Figure S1 in the Supporting Information).

Figure 1

Figure 1. Efficacy of 15 in a mouse model of neurogenesis. Compounds were administered using the indicated dose and method for 7 days, during which time mice were dosed IP daily with BrdU (50 mg kg–1 day–1) to label newborn hippocampal neurons. Data are shown as mean ± standard error of the mean (SEM).

High Resolution Image
Download MS PowerPoint Slide
Previous work had demonstrated that the preponderance of neuroprotective activity resided in a single enantiomer of the P7C3 class of compounds. The enantiomers of 18, 19, and 20 that are shown in Scheme 2 were the more active of each pair, suggesting a specific protein-binding partner. We also determined that tertiary alcohol 21 was more active than the initial hit 1, suggesting the presence of a hydrophobic binding site into which the methyl group could project. (3) These observations prompted the question of which, if either, enantiomer of fluorinated analogues such as 2 and 15 would display higher potency. In particular, we sought to determine whether fluorine would act as a polar group and occupy the binding site favored by the hydroxyl group of 18, 19, and 20 or act as a hydrophobic group and bind similarly to 21. Unfortunately, previous attempts to fluorinate an optically active precursor to 2 provided material with 0–20% ee, so developing an enantioselective synthesis remained a high priority.

Scheme 2

Scheme 2. Stereoselective Synthesis of (−)-15
High Resolution Image
Download MS PowerPoint Slide
Condensation of 3,6-dibromocarbazole (6) with the 3-Ns-protected glycidol derivative 22 provided the epoxide (−)-7 in 97% yield with 96% ee. (15) Epoxide ring opening with azide was quantitative and provided a substrate for fluorination, (+)-10. Comparison with the material formed from a Mitsunobu reaction with (S)-glycidol demonstrated that, as described by Sharpless and co-workers, (16) sulfonate 22 reacted by direct displacement of the leaving group rather than by epoxide opening/epoxide closure. Consistent with previous results, we found that reaction with MorphoDast was not stereospecific, as azidofluoride 11 was recovered with only 63% ee. We speculate that the common invertive mechanistic pathway was compromised by an intramolecular displacement with the carbazole nitrogen, yielding an aziridinium ion intermediate (not shown). This pathway would occur with overall retention and lower the observed optical purity. In contrast, we discovered that the reagent combination perfluorobutanesulfonyl fluoride and tetrabutylammonium difluorotriphenylsilicate (TBAT) yielded the desired fluoride with clean inversion. (17) Subsequent processing as before provided optically active (−)-15 with 95% ee. Recrystallization from isopropanol enriched the optical purity to 99% ee. The (+) enantiomer was similarly prepared starting from ent-22.
The pure enantiomers of 15 were first evaluated in the mouse model of hippocampal neuroprotection after they were dosed ICV. As shown in Figure 2, (−)-15 is highly active, whereas its enantiomer shows no neuroprotective activity in this assay. The more active enantiomer shows roughly the same activity as the racemic mixture at identical doses. We interpret this observation to mean that this in vivo assay cannot resolve the 2-fold difference in concentration between, for example, a single enantiomer at 10 μM and a racemic mixture at 10 μM (5 μM each enantiomer). X-ray crystallographic analysis of a single crystal of (−)-15 revealed it to be the S enantiomer (Figure S2 in the Supporting Information). Interestingly, the more active fluoride is enantiomeric to the more active enantiomer in the hydroxyl series (18–20). This observation implies that the binding partner for the P7C3 class of neuroprotective chemicals contains both a hydrophobic pocket, which can be occupied by the fluoride or methyl group, and a polar pocket, which preferentially accommodates a hydroxyl group.

Figure 2

Figure 2. Enantiomer-specific efficacy of 15 in a mouse model of neurogenesis. Compound was administered ICV at the indicated concentration (0.5 μL/h) for 7 days, during which time mice were dosed IP daily with BrdU (50 mg kg–1 day–1) to label newborn hippocampal neurons. The graph shows the mean ± SEM for each group (N = 4 or 5). Images are of representative stained sections. Scale bars = 0.3 mm.

High Resolution Image
Download MS PowerPoint Slide
The mouse model of neurogenesis involves protecting newborn hippocampal neurons from premature apoptotic cell death. We also sought to determine whether 15 could protect mature neurons from cell death. In this context, we had previously demonstrated that 1 and 2 could protect mature dopaminergic neurons within the SNc from toxicity associated with MPTP. (5) This mouse model of PD entails treating mice for 5 days with a toxic dose of MPTP (30 mg kg–1 day–1) to initiate cell death within the SNc. In the brain, MPTP is oxidized to 1-methyl-4-phenylpyridinium cation (MPP+), which is selectively transported into dopaminergic neurons within the SNc. (18) Within these cells, MPP+ acts as a mitochondrial poison, generating a pathology that resembles that of Parkinsonian patients. (19) Under our assay conditions, treatment with drug was initiated a full 24 h after the final dose of MPTP. This dosing regime ensured that any effect of the P7C3 class of compounds could be attributed to neuroprotective activity rather than to simply blocking the uptake or metabolism of MPTP. (20) Mice were administered drug twice daily for 21 days, after which time they were sacrificed by transcardial perfusion. Fixed brains were sectioned through the SNc at 30 μM intervals. Every fourth section was stained with antibodies specific to the enzyme tyrosine hydroxylase (TH). TH catalyzes the oxidation of l-tyrosine to l-3,4-dihydroxyphenylalanine (l-DOPA), which is the first step in the biosynthesis of dopamine. Accordingly, the number of TH+ cells provides a quantification of the neuroprotective efficacy of test compounds following MPTP exposure. Importantly, all microscopic analyses were performed blinded to the treatment group.
As shown in Figure 3, MPTP effects an approximately 50% reduction in the number of TH+ neurons under the chronic dosing protocol described above. Consistent with our earlier reports, 2 exhibits marked neuroprotective activity, showing a significant neuroprotective effect when administered at 5 mg kg–1 day–1 and protection resulting in around 75% rescue at a dose of 10 mg kg–1 day–1. (5) Encouragingly, 15 demonstrated even higher neuroprotective activity than 2, with the former showing significant activity at a dose of 1 mg kg–1 day–1 and rescuing over 85% of the TH+ neurons at the highest dose tested (10 mg kg–1 day–1). Moreover, the enantiomeric specificity observed in the MPTP model of PD mirrored that observed in the mouse model of neurogenesis. Specifically, (−)-(S)-15 was strongly protective, while the (+)-R enantiomer was indistinguishable from vehicle treatment under the conditions of the assay. In this side-by-side experiment, 15 appeared to be at least as effective as 2, a compound that has proven efficacy in several animal models of neurodegenerative disease.

Figure 3

Figure 3. Efficacy of 15 in the MPTP model of Parkinson’s disease. Mice were administered MPTP (30 mg kg–1 day–1) for 5 days. On the sixth day, treatment with drug was initiated at the indicated dose (IP, BID, 21 days) . Bars indicate numbers of tyrosine hydroxylase-positive (TH+) cells detected by immunohistochemical staining of the substantia nigra (mean ± SEM). Asterisks indicate p < 0.01 (*), p < 0.001 (**), or p < 0.0001 (***) relative to the vehicle (Veh) + MPTP group. The number of mice in each group is shown within the corresponding bar. Representative immunohistochemical pictures of TH staining in the SNc are shown for 5 mg kg–1 day–1 treatment groups. Scale bars = 300 μM.

High Resolution Image
Download MS PowerPoint Slide
The pharmacokinetic and toxicity profiles of 15 were evaluated using both in vivo and in vitro methods. We observed nearly complete metabolic stability in the presence of murine hepatocytes (t1/2 > 240 min) and good stability in the presence of liver microsomes (t1/2 values: mouse, 49 min; rat, >240 min; dog, 45 min; monkey, 81 min; human, 117 min). We then monitored plasma and brain levels of the compound following intravenous, oral, or intraperitoneal dosing. As shown in Table 1, 15 exhibited a dose-proportional increase in brain levels when dosed IP. Plasma bioavailability was higher when the compound was dosed IP as opposed to per os (PO) by oral gavage, but partitioning into the brain was superior when the compound was administered by oral gavage. We noted the same effect with 2, and thus, comparable brain levels are achieved either IP or by oral gavage. By all routes of administration, 15 was metabolically stable. While full pharmacokinetic profiling was performed with (±)-15, we additionally observed indistinguishable plasma and brain concentrations for racemic and (−)-15 at a single time point following intraperitoneal injection of 1, 3, 10, or 30 mg/kg doses (Figure S3 in the Supporting Information). These data are consistent with similar ADME properties for the racemic and optically active forms of 15.
Table 1. Pharmacokinetic Properties of (±)-15
administrationdose (mg/kg)AUC(brain) (μg·min/g)a%F (plasma/brain)AUCbrain/AUCplasmat1/2 (h)
IV10671 ± 14–1.17.4
IP10189 ± 3566/280.45>24
IP20319 ± 6890/480.2815
PO20388 ± 2938/290.819.6
a

Presented as mean ± SEM.

(−)-15 did not show significant toxicity toward the three human cancer cell lines tested (IC50 > 10 μM vs H2122, H2009, and HCC44). Likewise, we observed <15% inhibition of the hERG channel at 50 μM using a patch clamp assay. Several cytochrome P450s (CYP3A4, -2C9, -3D6, -2C8, -2B6) were insensitive to (−)-15, while CYP1A2 and CYP2C19 showed modest IC50 values of 20 and 1.9 μM, respectively. On the basis of the high protein binding of 15 (>99% (21)), free concentrations of the drug are unlikely to reach those concentrations. Finally, (−)-15 was screened through the NIH’s Psychoactive Drug Screening Program, and no compelling binding partners were identified. Of 47 neuronal receptors and channels tested, only the μ-opioid receptor (IC50 = 8.2 μM) and the peripheral benzodiazepine receptor [also known as translocator protein (TSPO)] (IC50 = 0.35 μM) showed any ligand displacement. The binding affinity of the former is clearly too weak to be causative for the biological activity we observed, provided that the in vitro data are predictive of binding in vivo. The relevance of binding to TSPO is less clear, however. While the total brain concentration remains in the low micromolar range for several hours after dosing, the free concentration is much lower. Moreover, while we observed enantiomeric specificity in the neurogenesis (Figure 2) and MPTP assays (Figure 3), both enantiomers of 15 bind TSPO with similarly weak affinities (0.35 and 0.68 μM). Finally, 2, which shows similar in vivo activity as (−)-15, binds TSPO more weakly (IC50 = 2.0 μM). A wide structural range of chemicals have been found to bind TSPO, from the eponymous benzodiazapines to cholesterol to porphyrins, (22) suggesting that it might represent a nonspecific binding partner for small molecules. Moreover, a tight-binding inhibitor of this protein showed no toxicity in phase I and II clinical trials for ALS and is currently in phase II trials for spinal muscular atrophy. (23) Overall, the clean receptor binding results, which are shown in full in Table S1 in the Supporting Information, are consistent with our observation that long-term treatment with 2 (up to 40 mg kg–1 day–1 for 21 days) or 15 (up to 10 mg kg–1 day–1 for 21 days) has no negative impact on the weight, behavior, or appearance of the treated animals.

Conclusions

Click to copy section linkSection link copied!
We have discovered a novel class of potent neuroprotective agents known as the P7C3 series of aminopropyl carbazoles. We have now synthesized and characterized an optimized member of this series that lacks an aniline moiety. Moreover, it exhibits improved polarity and is readily available as a single enantiomer. These characteristics improve its druglike properties compared with previously reported analogues. Here we have demonstrated that (−)-15 potently blocks neuron cell death under two conditions: apoptosis of newborn hippocampal neurons and MPTP-mediated killing of dopaminergic neurons in the substantia nigra. The latter effect is notable for almost complete protection in this model of Parkinson’s disease. Future reports will describe the effect of this neuroprotective chemical in a rat model of PD and mouse models of TBI. Likewise, we are actively seeking to validate the molecular target of the P7C3 class of compounds and will report the results of those studies in due course. Taken together, the data suggest that (−)-15 is a promising candidate for treating some of the most devastating neurological disorders—disorders that are likely to increase in prevalence and currently lack effective therapies.

Experimental Section

Click to copy section linkSection link copied!

General Methods

Unless otherwise stated, commercially available materials were used without further purification, and reactions were performed under a nitrogen atmosphere using freshly purified solvents. Solvents were purified using solvent purification columns purchased from Glass Contour (Laguna Beach, CA). All of the reactions were monitored by thin-layer chromatography (TLC) using E. Merck silica gel 60 F254 precoated plates (0.25 mm). Flash chromatography was performed with the indicated solvents using silica gel (particle size 0.032–0.063 μm) purchased from Sorbent Technologies. 1H and 13C NMR spectra were recorded on a Varian Inova 400 or 500 spectrometer. Chemical shifts are reported relative to internal solvent. Electrospray ionization mass spectrometry (ESI-MS) was performed on an Agilent 2010 LC–MS instrument. Optical rotations were measured at 20 °C on a Rudolph Research Analytical Autopol IV polarimeter. Compounds (±)-7, 10, and 16 were synthesized as previously described. (3, 4) All of the synthetic compounds were confirmed to be ≥95% pure by reversed-phase HPLC and 1H NMR analyses.

N-(6-Methoxypyridin-2-yl)-4-nitrobenzenesulfonamide

A solution of 6-methoxypyridin-2-ylamine (24) (206.8 mg, 1.66 mmol) and pyridine (0.2 mL) in methylene chloride (8.0 mL) was stirred for 30 min before being cooled in an ice bath. 4-Nitrobenzenesulfonyl chloride (383.9 mg, 1.73 mmol) was added slowly to the cold stirring solution, and the ice bath was removed 10 min later. The reaction mixture was stirred overnight and then condensed, and the dark-colored mixture was purified on an automated flash chromatography system in 0–10% MeOH/dichloromethane (DCM) to provide the nosylate as a yellow liquid in 55% yield. 1H NMR (CDCl3, 400 MHz): δ 8.34 (d, J = 8.9 Hz, 2H), 8.14 (d, J = 8.9 Hz, 2H), 7.53 (t, J = 8.0 Hz, 1H), 7.35–7.29 (m, 1H), 6.81 (d, J = 7.7 Hz, 1H), 6.46 (d, J = 8.2 Hz, 1H), 3.74 (s, 3H). 13C NMR (CDCl3, 100 MHz): δ 53.9, 103.7, 106.7, 124.5, 141.1, 145.4, 147.6, 163.7. ESI-MS (m/z): 309.9 [M + 1]+; C12H11N3O5S requires 309.04.

(−)-(S)-3,6-Dibromo-9-(oxiran-2-ylmethyl)-9H-carbazole [(−)-(S)-7]

In a modification of a published method, (17) a stirred solution of 3,6-dibromocarbazole (6.27 g, 19.3 mmol) and powdered potassium hydroxide (1.30 g, 23.2 mmol) in dimethylformamide (DMF) (100 mL) was cooled in ice before the dropwise addition of (R)-glycidyl-3-nitrobenzenesulfonate (22) (18) (5.01 g, 19.3 mmol). The ice bath was removed, and the reaction mixture was stirred overnight at ambient temperature, diluted with water, and washed several times with water and then brine. The organic layer was dried over Na2SO4, filtered, and concentrated to give epoxide (−)-7 in quantitative yield, which was used without additional purification. 1H NMR (CDCl3, 400 MHz): δ 8.13 (d, J = 2.0 Hz, 2H), 7.57 (dd, J = 8.7, 1.8 Hz, 2H), 7.39–7.31 (m, 2H), 4.65 (dd, J = 16.0, 2.5 Hz, 1H), 4.28 (dd, J = 16.1, 5.0 Hz, 1H), 3.32 (ddd, J = 5.2, 2.6, 1.3 Hz, 1H), 2.82 (t, J = 4.3 Hz, 1H), 2.50 (dd, J = 4.7, 2.6 Hz, 1H). 13C NMR (CDCl3, 100 MHz): δ 45.0, 45.1, 50.6, 110.7, 112.8, 123.4, 123.8, 129.5, 139.8. Poor ionization precluded analysis by mass spectrometry. HPLC (ChiralPak AD-H, 1.0 mL/min 1% iPrOH/hexanes): tR(major) = 24.3–34.0 min; tR(minor) = 48.4–58.6 min; ee = 95.9%. [α]D20 = −5.74 (c = 0.244, THF).

N-(3-(3,6-Dibromo-9H-carbazol-9-yl)-2-hydroxypropyl)-N-(6-methoxypyridin-2-yl)-4-nitrobenzenesulfonamide (8)

n-BuLi (0.65 mL of a 2.5 M solution in hexanes) was added dropwise to a solution of N-(6-methoxypyridin-2-yl)-4-nitrobenzenesulfonamide (278.7 mg, 0.90 mmol) in DMF (3.0 mL) at 0 °C. The solution was stirred for 15 min before the addition of 3,6-dibromo-9-(oxiran-2-ylmethyl)-9H-carbazole (7) (265.1 mg, 0.70 mmol). The reaction mixture was heated to 80 °C for 4 h, after which more epoxide 7 (113.0 mg, 0.3 mmol) was added. The reaction mixture was stirred overnight at 80 °C, cooled, diluted with EtOAc, and washed twice with water, twice with 1 N NaOH, twice more with water, and finally brine. The crude mixture was purified on an automated flash chromatography system in 0–10% MeOH/DCM to provide a light-orange solid in 12.5% yield. 1H NMR (CDCl3, 400 MHz): δ 8.17 (d, J = 1.9 Hz, 2H), 8.04 (d, J = 9.2 Hz, 2H), 7.56 (dd, J = 8.7, 2.0 Hz, 2H), 7.44 (t, J = 7.9 Hz, 1H), 7.38 (d, J = 8.7 Hz, 2H), 7.05–6.77 (m, 2H), 6.48 (d, J = 7.7 Hz, 1H), 6.40 (d, J = 8.1 Hz, 1H), 4.43 (ddd, J = 15.5, 13.8, 7.5 Hz, 3H), 4.22–4.03 (m, 1H), 3.92 (dd, J = 15.3, 8.9 Hz, 1H), 3.49 (s, 3H). 13C NMR (CDCl3, 100 MHz): δ 163.9, 155.5, 140.9, 140.0, 129.4, 126.1, 125.7, 123.7, 123.4, 120.2, 114.6, 112.8, 111.2, 107.4, 105.0, 69.1, 68.1, 53.7, 25.8. ESI-MS (m/z): 732.6 [M + HCOO]−; C27H22Br2N4O6S requires 688.0.

3-((3,6-Dibromo-9H-carbazol-9-yl)methyl)-1-((4-nitrophenyl)sulfonyl)-2,3-dihydroimidazo[1,2-a]pyridin-5(1H)-one (9)

MorphoDast (100 μL, 0.82 mmol) was added to a solution of alcohol 8 (60.2 mg, 0.087 mmol) in methylene chloride (2.0 mL). The reaction mixture was stirred overnight, and the reaction was quenched by the addition by an equivalent volume of saturated aqueous sodium bicarbonate. The mixture was extracted three times with methylene chloride. The combined organic layers were dried over Na2SO4, filtered, concentrated, and purified by preparative TLC in 5% MeOH/DCM to provide the pyridone as a yellow solid in 21% yield. 1H NMR (CDCl3, 400 MHz): δ 8.26–8.13 (m, 2H), 8.06 (d, J = 1.8 Hz, 2H), 7.48 (dd, J = 8.7, 1.9 Hz, 2H), 7.39 (d, J = 8.7 Hz, 2H), 7.35 (dd, J = 9.1, 7.5 Hz, 1H), 7.01–6.80 (m, 2H), 6.22 (dd, J = 9.1, 0.8 Hz, 1H), 5.87 (dd, J = 7.5, 0.8 Hz, 1H), 5.31 (s, 1H), 5.28 (dd, J = 7.4, 3.2 Hz, 1H), 4.88 (dd, J = 15.2, 3.1 Hz, 1H), 4.70 (dd, J = 15.1, 7.5 Hz, 1H), 4.15 (dd, J = 10.2, 8.3 Hz, 1H), 3.87 (dd, J = 10.2, 1.3 Hz, 1H). 13C NMR (CDCl3, 100 MHz): δ 161.3, 146.3, 144.9, 142.4, 139.4, 129.8, 125.7, 123.9, 123.6, 117.8, 113.2, 111.4, 110.3, 95.2, 86.3, 53.7, 52.0. ESI-MS (m/z): 700.6 [M + HCOO]−; C26H18Br2N4O5S requires 655.9.

(+)-(S)-1-Azido-3-(3,6-dibromo-9H-carbazol-9-yl)propan-2-ol [(+)-(S)-10]

A 20% aqueous solution of sodium azide (75 mL) was added to a mixture of (S)-(−)-7 (7.79 g, 20.4 mmol) and tetrahydrofuran (THF) (65 mL), and the mixture was heated to 75 °C. A further 20 mL of a 20% aqueous solution of sodium azide was added after 24 h to ensure complete conversion of the epoxide. The biphasic mixture was condensed under reduced pressure, diluted with EtOAc, and washed twice with water and then brine. The organic layer was dried over Na2SO4, filtered, and concentrated to give the azido alcohol in 91% yield, which was used without further purification. 1H NMR (CDCl3, 400 MHz): δ 8.06 (d, J = 1.9 Hz, 2H), 7.53 (dd, J = 8.7, 2.0 Hz, 2H), 7.28 (d, J = 8.4 Hz, 2H), 4.26 (dd, J = 6.1, 1.6 Hz, 2H), 4.23–4.14 (m, 1H), 3.44 (dd, J = 12.6, 4.3 Hz, 1H), 3.30 (dd, J = 12.6, 5.6 Hz, 1H), 2.48 (s, 1H). 13C NMR (CDCl3, 100 MHz): δ 46.4, 54.1, 69.5, 110.6, 110.7, 112.7, 123.3, 123.3, 123.6, 129.4, 139.5. ESI-MS (m/z): 466.6 [M + HCOO]−; C15H12Br2N4O requires 421.9. [α]D20 = +3.18 (c = 0.26, THF).

(−)-(R)-9-(3-Azido-2-fluoropropyl)-3,6-dibromo-9H-carbazole [(−)-(R)-11]

Following a published procedure, diisopropylethylamine (7.75 mL, 44.5 mmol) and toluene (140 mL) were added alternatingly (ca. 20 portions each) to a mixture of tetrabutylammonium difluorotriphenylsilicate (TBAT) (9.50 g, 17.6 mmol) and (S)-1-azido-3-(3,6-dibromo-9H-carbazol-9-yl)propan-2-ol (7.41 g, 17.5 mmol) at room temperature. (19) Perfluoro-1-butanesulfonyl fluoride (PBSF) (6.91 mL, 38.5 mmol) was added dropwise, and the reaction mixture was stirred overnight at ambient temperature. The mixture was concentrated and purified by automated chromatography (SiO2, 50% DCM/hexanes) to provide the fluoro azide in 70% yield as a white solid. 1H NMR (CDCl3, 400 MHz): δ 8.14 (t, J = 2.3 Hz, 2H), 7.64–7.52 (m, 2H), 7.32 (dd, J = 8.7, 1.8 Hz, 2H), 5.12–4.85 (m, 1H), 4.54 (ddt, J = 17.9, 5.4, 2.4 Hz, 2H), 3.58 (ddd, J = 17.7, 13.5, 4.5 Hz, 1H), 3.40 (ddd, J = 24.1, 13.5, 4.7 Hz, 1H). 13C NMR (CDCl3, 100 MHz): δ 44.2 (d, JC–F = 23.9 Hz), 51.6 (d, JC–F = 23.9 Hz), 90.0 (d, JC–F = 177.6 Hz), 110.5 (d, JC–F = 1.3 Hz), 113.1, 123.5 (d, JC–F = 2.2 Hz), 123.9, 129.6, 139.5. ESI-MS (m/z): 468.7 [M + HCOO]−; C15H11Br2FN4 requires 423.9. HPLC (ChiralPak AD-H, 1.0 mL/min 0.5% iPrOH/hexanes): tR(minor) = 25.0–29.1 min; tR(major) = 29.4–40.7 min; ee = 96.2%. [α] D20 = −5.90 (c = 0.217, THF).

(+)-(S)-3-(3,6-Dibromo-9H-carbazol-9-yl)-2-fluoropropan-1-amine [(S)-(+)-12]

Triphenylphosphine (3.24, 12.3 mmol) was added to a solution of azide (−)-(R)-11 (5.10 g, 12.0 mmol) in THF (80 mL). The cloudy mixture was heated at 65 °C overnight. Water was added to the cooled reaction mixture, and the resulting mixture was stirred for 6 h before volatile solvents were removed under reduced pressure. The viscous mixture was diluted with EtOAc and washed twice with water and then brine. The organic layer was dried over Na2SO4, filtered, and concentrated to give a yellow waxy residue. Sufficient cold methylene chloride was added to dissolve the waxy residue (ca. 100 mL), and then at 0 °C 1 M HCl was added dropwise to precipitate the hydrochloride salt. The slurry was stirred for about 20 min before it was filtered and then washed with cold DCM several times and finally with hexanes. The powdery solid (5.29 g, quantitative) was dried on a fritted funnel and contained less than 1% PPh3O byproduct. The salt was freebased by adding a saturated solution of sodium bicarbonate (90.0 mL) to a milky mixture of the amine HCl salt (5.29 g) in methylene chloride (90.0 mL) with Et3N (3.0 mL). The solution was stirred for 1 h until the organic layer was translucent. The organic layer was separated, and the aqueous phase was extracted with methylene chloride. The combined organic layers were dried over Na2SO4, filtered, and concentrated to give the free amine as an off-white solid. 1H NMR (CDCl3, 400 MHz): δ 8.15 (d, J = 2.0 Hz, 2H), 7.57 (dd, J = 8.8, 1.9 Hz, 2H), 7.36 (d, J = 8.7 Hz, 2H), 4.85 (dtt, J = 47.9, 6.1, 4.4 Hz, 1H), 4.67–4.39 (m, 2H), 3.22–2.78 (m, 2H). 13C NMR (CD3OD, 100 MHz): δ 141.1, 130.5, 125.1, 124.3, 113.8, 112.4, 112.4, 91.2 (d, JC–F = 172.4 Hz), 45.5 (d, JC–F = 20.4 Hz), 42.1 (d, JC–F = 20.4 Hz). [α]D20 = +8.21 (c = 0.268, MeOH). ESI-MS (m/z): 398.7 [M + 1]+; C15H13Br2FN2 requires 397.94.

1-(3,6-Dibromo-9H-carbazol-9-yl)-3-((6-methoxypyridin-2-yl)amino)propan-2-ol (17)

1-Amino-3-(3,6-dibromo-9H-carbazol-9-yl)propan-2-ol (16) (60.1 mg, 0.15 mmol), 2-iodo-6-methoxypyridine (13) (35.9 mg, 0.15 mmol), copper(I) iodide (2.3 mg, 0.012 mmol), and cesium carbonate (100.9 mg, 0.31 mmol) were combined in an oven-dried vial under nitrogen. Dimethyl sulfoxide (DMSO) (0.3 mL) and 2,2,6,6-tetramethyl-3,5-heptanedione (14) (3.5 μL, 0.017 mmol) were then added. The reaction mixture was stirred overnight at ambient temperature, diluted with EtOAc, and washed several times with water and then brine. The organic layer was dried over Na2SO4, filtered, and concentrated. The well-dried solid was dissolved in 80% DCM/hexanes, passed through a short silica plug, and washed with DCM to remove unreacted amine. The filtrate was condensed to give a residue in 30% yield. 1H NMR (CDCl3, 500 MHz): δ 8.15 (d, J = 2.0 Hz, 2H), 7.57 (dd, J = 8.6, 2.0 Hz, 2H), 7.36 (m, 3H), 6.09 (d, J = 7.9 Hz, 1H), 6.02 (d, J = 7.8 Hz, 1H), 4.55 (bs, 1H), 4.45–4.22 (m, 3H), 3.76 (s, 3H), 3.50 (d, J = 14.7 Hz, 1H), 3.26 (dt, J = 14.1, 5.6 Hz, 1H). 13C NMR (CDCl3, 100 MHz): δ 163.3, 157.4, 140.2, 139.2, 128.8, 123.2, 122.9, 112.0, 110.5, 99.9, 97.4, 70.2, 53.3, 46.5, 46.3. ESI-MS (m/z): 503.7 [M + H]+; C21H19Br2N3O2 requires 503.0.

(S)-N-(3-(3,6-Dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine [(−)-(S)-15

First, (S)-12 (72.2 mg, 0.18 mmol), 2-iodo-6-methoxypyridine (14) (45.4 mg, 0.19 mmol), copper(I) iodide (2.9 mg, 0.015 mmol), and cesium carbonate (119.4 mg, 0.36 mmol) were added to an oven-dried vial, which was then purged with nitrogen for 10 min. Then DMSO (0.36 mL) and 14 (4 μL, 0.019 mmol) were added. The reaction mixture was heated at 40 °C for 3 h. The cooled mixture was diluted with EtOAc and washed three times with a 9:1 saturated NH4Cl/NH4OH solution, three times with water, and then brine. The organic layer was dried over Na2SO4, filtered, and concentrated. The well-dried solid was dissolved in methylene chloride and passed through a short silica plug, which removed the small amount of unreacted amine. The filtrate was condensed to give a white solid, which was purified on an automated flash chromatography system in 50–80% DCM/hexanes to provide (−)-(S)-15 as a white solid in 61% yield with 96% ee, which was stored under nitrogen. Recrystallization to enhance the enantiomeric excess was carried out by heating a solution of 15.8 mg of the purified product in 1.0 mL of isopropanol. Thin needles formed over 24 h at room temperature. The overall yield from (S)-12 was 59% with 98.5% ee. Single crystals suitable for X-ray diffraction were grown by diffusion of hexanes into a concentrated solution of (−)-15 in dichloroethane (see Figure S2 in the Supporting Information). 1H NMR (CDCl3, 400 MHz): δ 8.16 (d, J = 1.9 Hz, 2H), 7.56 (d, J = 1.9 Hz, 2H), 7.35 (t, J = 7.8 Hz, 1H), 7.30 (d, J = 8.7 Hz, 1H), 6.04 (dd, J = 32.7, 8.0 Hz, 2H), 5.29–5.02 (dm, 1H), 4.65–4.46 (m, 3H), 3.87–3.74 (m, 1H), 3.70 (s, 3H), 3.66–3.49 (m, 1H). 13C NMR (CDCl3, 100 MHz): δ 163.7, 156.9, 140.3, 139.7, 129.5, 123.9, 123.4, 112.8, 110.7 (d, JC–F = 1.8 Hz), 99.6, 98.2, 91.4 (d, JC–F = 174.9 Hz), 45.31 (d, JC–F = 23.9 Hz), 43.6 (d, JC–F = 22.0 Hz). ESI-MS (m/z): 505.8 [M + 1]+; C22H19Br2FN2O requires 505.0. HPLC (ChiralPak IA, 1.0 mL/min 100% MeOH): tR(major) = 8.37–10.02 min; tR(minor) = 10.26–11.26 min. [α]D20 = −9.5 (c = 0.46, THF).

Animal Studies

All of the animal studies were performed in accordance with the ethical guidelines established by UT Southwestern and the University of Iowa.

In Vivo Neuroprotection Assay

Test compounds were evaluated as described previously. (2) Compounds were infused ICV into the left lateral ventricle of four adult (12 week old) wild-type C57BL/J6 mice by means of surgically implanted Alzet osmotic minipumps that delivered solution into the animals at a constant rate of 0.5 μL/h for 7 days. Alternatively, compounds were administered IP twice daily. Bromodeoxyuridine (BrdU) was injected IP at 50 mg kg–1 day–1 for 6 days during pump infusion. Twenty-four hours after the final BrdU administration, mice were sacrificed by transcardial perfusion with 4% paraformaldehyde at pH 7.4, and their brains were processed for immunohistochemical detection of incorporated BrdU in the subgranular zone (SGZ). Dissected brains were immersed in 4% paraformaldehyde overnight at 4 °C and then cryoprotected in sucrose before being sectioned into 40 μm thick free-floating sections. Unmasking of BrdU antigen was achieved by incubation of tissue sections for 2 h in 50% formamide/2× saline sodium citrate (SSC) at 65 °C followed by a 5 min wash in 2× SSC and subsequent incubation for 30 min in 2 M HCl at 37 °C. Sections were processed for immunohistochemical staining with mouse monoclonal anti-BrdU (1:100). The number of BrdU+ cells in the entire dentate gyrus SGZ in the contralateral hemisphere (opposite side of the surgically implanted pump) was quantified by counting BrdU+ cells within the SGZ and dentate gyrus in every fifth section throughout the entire hippocampus and then normalizing for dentate gyrus volume.

MPTP Assay

As previously reported, (5) adult male C57Bl/6 mice were individually housed for 1 week and then injected IP daily for 5 days with 30 mg kg–1 day–1 free-base MPTP (Sigma). On day 6, 24 h after the mice received the fifth and final dose of MPTP, daily treatment with compound was initiated. Mice received twice-daily doses of each compound (or vehicle) for the following 21 days, after which mice were sacrificed by transcardial perfusion with 4% paraformaldehyde. The brains were dissected, fixed overnight in 4% paraformaldehyde, and cryoprotected in sucrose for freezing by standard procedures. Frozen brains were sectioned through the striatum and SNc at 30 μM intervals, and every fourth section (spaced 120 μM apart) was stained with antibodies directed against tyrosine hydroxylase (TH) (Abcam, rabbit anti-TH, 1:2500). Diaminobenzidine was used as a chromagen, and tissue was counter-stained with hematoxylin to aid in visualization of the neuroanatomy. Images were analyzed with a Nikon Eclipse 90i motorized research microscope with Plan Apo lenses coupled with Metamorph Image Acquisition software (Nikon). TH+ neurons were counted with ImageJ software (NIH) in every section by two blinded investigators, and the results were averaged and multiplied by the sectioning interval to determine the total number of TH+ neurons per SNc.

Pharmacokinetic Analysis

15 was formulated in 5% DMSO/10% cremophor EL (Sigma, St. Louis, MO)/85% D5W (5% dextrose in water, pH 7.2). Adult mice were dosed IV, IP or via oral gavage (PO) in a total volume of 0.2 mL. Animals were sacrificed at varying times after dosing by inhalation overdose of CO2. Whole blood was collected with a syringe and needle coated with anticoagulant citrate dextrose (ACD) solution (sodium citrate). The blood was subsequently centrifuged at 9300g for 10 min to isolate plasma. Plasma was stored at −80 °C until analysis. Brains were isolated from mice immediately after sacrifice, rinsed extensively with phosphate-buffered saline (PBS), blotted dry, weighed, and snap-frozen in liquid nitrogen. Lysates were prepared by homogenizing the brain tissue in a 3-fold volume of PBS (weight of brain in g × 3 = volume in mL of added PBS). The total lysate volume was estimated as the volume of added PBS plus the volume of brain. Either plasma or brain (100 μL) was processed by addition of 200 μL of acetonitrile containing 0.15% formic acid to precipitate plasma or tissue protein and release bound drug. This mixture was vortexed for 15 s and then centrifuged at 13120g for 5 min, and the supernatant was analyzed directly by HPLC/MS/MS. Standard curves were prepared by addition of compound to blank plasma or blank brain lysate. A value 3-fold above the signal obtained from blank plasma or brain lysate was designated as the limit of detection (LOD). The limit of quantitation (LOQ) was defined as the lowest concentration at which back-calculation yielded a concentration within 20% of the theoretical value. Pharmacokinetic parameters were calculated using the noncompartmental analysis tool of WinNonLin (Pharsight). Bioavailability was calculated as (AUCoral/AUCIV) × (DoseIV/Doseoral) × 100%, where AUC denotes the area under the concentration–time curve). The brain:blood ratio was calculated using AUC values.

Plasma Protein Binding

Protein binding of compound 15 was determined using a recently described ultracentrifugation method; (23) 100% compound recovery was achieved during the assay, indicating no loss due to absorption to plastic.

Supporting Information

Click to copy section linkSection link copied!

Table of screening results from the Psychoactive Drug Screening Program, X-ray crystal structure of (−)-15, comparison of plasma and brain levels for rac-15 and (−)-15, and spectra of synthetic materials. This material is available free of charge via the Internet at http://pubs.acs.org.

Terms & Conditions

Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: http://pubs.acs.org/page/copyright/permissions.html.

Author Information

Click to copy section linkSection link copied!
  • Corresponding Authors
    • Andrew A. Pieper - Departments of Psychiatry, Neurology, and Veterans Affairs, University of Iowa Carver College of Medicine, 200 Hawkins Avenue, Iowa City, Iowa 52242, United States;  Email: [email protected]
    • Joseph M. Ready - Departments of †Biochemistry and ‡Neuroscience, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9038, United States;  Departments of Psychiatry, Neurology, and Veterans Affairs, University of Iowa Carver College of Medicine, 200 Hawkins Avenue, Iowa City, Iowa 52242, United States;  National Institute of Mental Health Psychoactive Drug Screening Program, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States;  Email: [email protected]
  • Authors
    • Jacinth Naidoo - Departments of †Biochemistry and ‡Neuroscience, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9038, United States;  Departments of Psychiatry, Neurology, and Veterans Affairs, University of Iowa Carver College of Medicine, 200 Hawkins Avenue, Iowa City, Iowa 52242, United States;  National Institute of Mental Health Psychoactive Drug Screening Program, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
    • Hector De Jesus-Cortes - Departments of Psychiatry, Neurology, and Veterans Affairs, University of Iowa Carver College of Medicine, 200 Hawkins Avenue, Iowa City, Iowa 52242, United States
    • Paula Huntington - Departments of †Biochemistry and ‡Neuroscience, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9038, United States;  Departments of Psychiatry, Neurology, and Veterans Affairs, University of Iowa Carver College of Medicine, 200 Hawkins Avenue, Iowa City, Iowa 52242, United States;  National Institute of Mental Health Psychoactive Drug Screening Program, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
    • Sandi Estill - Departments of †Biochemistry and ‡Neuroscience, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9038, United States;  Departments of Psychiatry, Neurology, and Veterans Affairs, University of Iowa Carver College of Medicine, 200 Hawkins Avenue, Iowa City, Iowa 52242, United States;  National Institute of Mental Health Psychoactive Drug Screening Program, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
    • Lorraine K. Morlock - Departments of †Biochemistry and ‡Neuroscience, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9038, United States;  Departments of Psychiatry, Neurology, and Veterans Affairs, University of Iowa Carver College of Medicine, 200 Hawkins Avenue, Iowa City, Iowa 52242, United States;  National Institute of Mental Health Psychoactive Drug Screening Program, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
    • Ruth Starwalt - Departments of †Biochemistry and ‡Neuroscience, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9038, United States;  Departments of Psychiatry, Neurology, and Veterans Affairs, University of Iowa Carver College of Medicine, 200 Hawkins Avenue, Iowa City, Iowa 52242, United States;  National Institute of Mental Health Psychoactive Drug Screening Program, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
    • Thomas J. Mangano - National Institute of Mental Health Psychoactive Drug Screening Program, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
    • Noelle S. Williams - Departments of †Biochemistry and ‡Neuroscience, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9038, United States;  Departments of Psychiatry, Neurology, and Veterans Affairs, University of Iowa Carver College of Medicine, 200 Hawkins Avenue, Iowa City, Iowa 52242, United States;  National Institute of Mental Health Psychoactive Drug Screening Program, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
  • Notes
    The authors declare no competing financial interest.

Acknowledgment

Click to copy section linkSection link copied!

We thank Prof. Jef De Brabander (UT Southwestern) for helpful discussions regarding Cu-catalyzed amination and the NIH’s Psychoactive Drug Screening Program at the University of North Carolina. Funding was provided by the Edward N. and Della C. Thome Memorial Foundation and the Welch Foundation (I-1612) (to J.M.R.) and the NSF (2012140236-02) (to H.D.J.-C.). Additional support was received from the NIH (R01 MH087986) to A.A.P. and an unrestricted endowment provided to Steven L. McKnight by an anonymous donor.

Abbreviations Used

Click to copy section linkSection link copied!
ALS

amyotrophic lateral sclerosis

PD

Parkinson’s disease

TBI

traumatic brain injury

BrdU

bromodeoxyuridine

MPTP

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

SOD

superoxide dismutase

ICV

intracerebroventricularly

IP

intraperitoneally

PO

per os (by mouth)

TH

tyrosine hydroxylase

SNc

substantia nigra

AUC

area under the curve.

References

Click to copy section linkSection link copied!

This article references 24 other publications.

  1. 1
    (a) Lees, A. J.; Hardy, J.; Revesz, T. Parkinson’s Disease Lancet 2009, 373, 2055– 2066
    Google Scholar
    1a
    Parkinson's disease
    Lees, Andrew J.; Hardy, John; Revesz, Tamas
    Lancet (2009), 373 (9680), 2055-2066CODEN: LANCAO; ISSN:0140-6736. (Elsevier Ltd.)
    A review. Summary: Parkinson's disease is a common progressive bradykinetic disorder that can be accurately diagnosed. It is characterised by the presence of severe pars-compacta nigral-cell loss, and accumulation of aggregated α-synuclein in specific brain stem, spinal cord, and cortical regions. The main known risk factor is age. Susceptibility genes including α-synuclein, leucine rich repeat kinase 2 (LRRK-2), and glucocerebrosidase (GBA) have shown that genetic predisposition is another important causal factor. Dopamine replacement therapy considerably reduces motor handicap, and effective treatment of assocd. depression, pain, constipation, and nocturnal difficulties can improve quality of life. Embryonic stem cells and gene therapy are promising research therapeutic approaches.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1ans7w%253D&md5=ae632b0ac91f4e5ee017bf2bf21f5926
    (b) Hebert, L. E.; Scherr, P. A.; Bienias, J. L.; Bennett, D. A.; Evans, D. A. State-Specific Projections through 2025 of Alzheimer Disease Prevalence Neurology 2004, 62, 1645
    Google Scholar
    There is no corresponding record for this reference.
  2. 2
    (a) Pieper, A. A.; Xie, S.; Capota, E.; Estill, S. J.; Zhong, J.; Long, J. M.; Becker, G. L.; Huntington, P.; Goldman, S. E.; Shen, C.-H.; Capota, M.; Britt, J. K.; Kotti, T.; Ure, K.; Brat, D. J.; Williams, N. S.; MacMillan, K. S.; Naidoo, J.; Melito, L.; Hsieh, J.; De Brabander, J.; Ready, J. M.; McKnight, S. L. Discovery of a Proneurogenic, Neuroprotective Chemical Cell 2010, 142, 39– 51
    Google Scholar
    2a
    Discovery of a proneurogenic, neuroprotective chemical
    Pieper, Andrew A.; Xie, Shanhai; Capota, Emanuela; Estill, Sandi Jo; Zhong, Jeannie; Long, Jeffrey M.; Becker, Ginger L.; Huntington, Paula; Goldman, Shauna E.; Shen, Ching-Han; Capota, Maria; Britt, Jeremiah K.; Kotti, Tiina; Ure, Kerstin; Brat, Daniel J.; Williams, Noelle S.; MacMillan, Karen S.; Naidoo, Jacinth; Melito, Lisa; Hsieh, Jenny; De Brabander, Jef; Ready, Joseph M.; McKnight, Steven L.
    Cell (Cambridge, MA, United States) (2010), 142 (1), 39-51CODEN: CELLB5; ISSN:0092-8674. (Cell Press)
    An in vivo screen was performed in search of chems. capable of enhancing neuron formation in the hippocampus of adult mice. Eight of 1000 small mols. tested enhanced neuron formation in the subgranular zone of the dentate gyrus. Among these was an aminopropyl carbazole, designated P7C3, endowed with favorable pharmacol. properties. In vivo studies gave evidence that P7C3 exerts its proneurogenic activity by protecting newborn neurons from apoptosis. Mice missing the gene encoding neuronal PAS domain protein 3 (NPAS3) are devoid of hippocampal neurogenesis and display malformation and electrophysiol. dysfunction of the dentate gyrus. Prolonged administration of P7C3 to npas3-/- mice cor. these deficits by normalizing levels of apoptosis of newborn hippocampal neurons. Prolonged administration of P7C3 to aged rats also enhanced neurogenesis in the dentate gyrus, impeded neuron death, and preserved cognitive capacity as a function of terminal aging.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1Cjt7Y%253D&md5=7ed01874bd3e1b5cde587b2bc244741d
    (b) McKnight, S. L.; Pieper, A. A.; Ready, J. M.; De Brabander, J. Proneurogenic Compounds. U.S. Patent 8,604,074, 2013.
    Google Scholar
    There is no corresponding record for this reference.
    (c) McKnight, S. L.; Pieper, A. A.; Ready, J. M.; De Brabander, J. Proneurogenic Compounds. U.S. Patent 8,362,277, 2013.
    Google Scholar
    There is no corresponding record for this reference.
  3. 3
    MacMillan, K. S.; Naidoo, J.; Liang, J.; Melito, L.; Williams, N. S.; Morlock, L.; Huntington, P. J.; Estill, S. J.; Longgood, J.; Becker, G. L.; McKnight, S. L.; Pieper, A. A.; De Brabander, J. K.; Ready, J. M. Development of Proneurogenic, Neuroprotective Small Molecules J. Am. Chem. Soc. 2011, 133, 1428– 1437
    Google Scholar
    There is no corresponding record for this reference.
  4. 4
    Naidoo, J.; Bemben, C. J.; Allwein, S. R.; Liang, J.; Pieper, A. A.; Ready, J. M. Development of a Scalable Synthesis of P7C3-A20, a Potent Neuroprotective Agent Tetrahedron Lett. 2013, 54, 4429– 4431
    Google Scholar
    There is no corresponding record for this reference.
  5. 5
    De Jesus-Cortes, H.; Xu, P.; Drawbridge, J.; Estill, S. J.; Huntington, P.; Tran, S.; Britt, J.; Tesla, R.; Morlock, L.; Naidoo, J.; Melito, L. M.; Wang, G.; Williams, N. S.; Ready, J. M.; McKnight, S. L.; Pieper, A. A. Neuroprotective Efficacy of Aminopropyl Carbazoles in a Mouse Model of Parkinson Disease Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 17010– 17015
    Google Scholar
    There is no corresponding record for this reference.
  6. 6
    Tesla, R.; Wolf, H. P.; Xu, P.; Drawbridge, J.; Estill, S. J.; Huntington, P.; McDaniel, L.; Knobbe, W.; Burket, A.; Tran, S.; Starwalt, R.; Morlock, L.; Naidoo, J.; Williams, N. S.; Ready, J. M.; McKnight, S. L.; Pieper, A. A. Neuroprotective Efficacy of Aminopropyl Carbazoles in a Mouse Model of Amyotrophic Lateral Sclerosis Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 17016– 17021
    Google Scholar
    There is no corresponding record for this reference.
  7. 7
    Blaya, M. O.; Bramlett, H.; Nadoo, J.; Pieper, A. A.; Dietrich, W. D., III. Neuroprotective Efficacy of a Proneurogenic Compound after Traumatic Brain Injury J. Neurotrauma 2014, 31, 476– 468
    Google Scholar
    7
    Neuroprotective efficacy of a proneurogenic compound after traumatic brain injury
    Blaya Meghan O; Bramlett Helen M; Naidoo Jacinth; Pieper Andrew A; Dietrich W Dalton
    Journal of neurotrauma (2014), 31 (5), 476-86 ISSN:.
    Traumatic brain injury (TBI) is characterized by histopathological damage and long-term sensorimotor and cognitive dysfunction. Recent studies have reported the discovery of the P7C3 class of aminopropyl carbazole agents with potent neuroprotective properties for both newborn neural precursor cells in the adult hippocampus and mature neurons in other regions of the central nervous system. This study tested, for the first time, whether the highly active P7C3-A20 compound would be neuroprotective, promote hippocampal neurogenesis, and improve functional outcomes after experimental TBI. Sprague-Dawley rats subjected to moderate fluid percussion brain injury were evaluated for quantitative immunohistochemical and behavioral changes after trauma. P7C3-A20 (10 mg/kg) or vehicle was initiated intraperitoneally 30 min postsurgery and twice per day every day thereafter for 7 days. Administration of P7C3-A20 significantly reduced overall contusion volume, preserved vulnerable anti-neuronal nuclei (NeuN)-positive pericontusional cortical neurons, and improved sensorimotor function 1 week after trauma. P7C3-A20 treatment also significantly increased both bromodeoxyuridine (BrdU)- and doublecortin (DCX)-positive cells within the subgranular zone of the ipsilateral dentate gyrus 1 week after TBI. Five weeks after TBI, animals treated with P7C3-A20 showed significantly increased BrdU/NeuN double-labeled neurons and improved cognitive function in the Morris water maze, compared to TBI-control animals. These results suggest that P7C3-A20 is neuroprotective and promotes endogenous reparative strategies after TBI. We propose that the chemical scaffold represented by P7C3-A20 provides a basis for optimizing and advancing new pharmacological agents for protecting patients against the early and chronic consequences of TBI.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FhsFyltA%253D%253D&md5=b0b1e5150d33d05dfbf444d86bc16951
  8. 8
    Walker, A. K.; Rivera, P. D.; Wang, Q.; Chuang, J.-C.; Tran, S.; Osborne-Lawrence, S.; Estill, S. J.; Starwalt, R.; Huntington, P.; Morlock, L.; Naidoo, J.; Williams, N.; Ready, J. M.; Eisch, A. J.; Pieper, A. A.; Zigman, J. M. The P7C3-class of Neuroprotective Compounds Exerts Antidepressant Efficacy in Mice by Increasing Hippocampal Neurogenesis. Mol. Psychiatry 2014, in press
    Google Scholar
    There is no corresponding record for this reference.
  9. 9
    Asai-Coakwell, M.; March, L.; Dai, X. H.; DuVal, M.; Lopez, I.; French, C. R.; Famulski, J.; De Baere, E.; Francis, P. J.; Sundaresan, P.; Sauve, Y.; Koenekoop, R. K.; Berry, F. B.; Allison, W. T.; Waskiewicz, A. J.; Lehmann, O. J. Contribution of Growth Differentiation Factor 6-Dependent Cell Survival to Early-Onset Retinal Dystrophies Hum. Mol. Genet. 2013, 22, 1432– 1442
    Google Scholar
    9
    Contribution of growth differentiation factor 6-dependent cell survival to early-onset retinal dystrophies
    Asai-Coakwell, Mika; March, Lindsey; Dai, Xiao Hua; DuVal, Michele; Lopez, Irma; French, Curtis R.; Famulski, Jakub; De Baere, Elfride; Francis, Peter J.; Sundaresan, Periasamy; Sauve, Yves; Koenekoop, Robert K.; Berry, Fred B.; Allison, W. Ted; Waskiewicz, Andrew J.; Lehmann, Ordan J.
    Human Molecular Genetics (2013), 22 (7), 1432-1442CODEN: HMGEE5; ISSN:0964-6906. (Oxford University Press)
    Retinal dystrophies are predominantly caused by mutations affecting the visual phototransduction system and cilia, with few genes identified that function to maintain photoreceptor survival. The authors reasoned that growth factors involved with early embryonic retinal development would represent excellent candidates for such diseases. Here they show that mutations in the transforming growth factor-β (TGF-β) ligand Growth Differentiation Factor 6, which specifies the dorso-ventral retinal axis, contribute to Leber congenital amaurosis. Furthermore, deficiency of gdf6 results in photoreceptor degeneration, so demonstrating a connection between Gdf6 signaling and photoreceptor survival. In addn., in both murine and zebrafish mutant models, the authors observe retinal apoptosis, a characteristic feature of human retinal dystrophies. Treatment of gdf6-deficient zebrafish embryos with a novel aminopropyl carbazole, P7C3, rescued the retinal apoptosis without evidence of toxicity. These findings implicate for the first time perturbed TGF-β signaling in the genesis of retinal dystrophies, support the study of related morphogenetic genes for comparable roles in retinal disease and may offer addnl. therapeutic opportunities for genetically heterogeneous disorders presently only treatable with gene therapy.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktV2qu74%253D&md5=1b2b830f91e132831bba5ab9628f19a5
  10. 10

    Mice housed alone and without objects such as nesting material show decreased hippocampal neurogenesis, magnifying the effect of neuroprotective compounds.

    There is no corresponding record for this reference.
  11. 11

    Rough calculations suggested that the test compounds would reach a concentration of approximately 100 nM by the end of the testing period if all of the material remained in the brain.

    There is no corresponding record for this reference.
  12. 12
    Struk, L.; Sosnicki, J. G. Noncryogenic Synthesis of Functionalized 2-Methoxypyridines by Halogen–Magnesium Exchange Using Lithium Dibutyl(Isopropyl)Magnesate and Lithium Chloride Synthesis 2012, 44, 735– 746
    Google Scholar
    12
    Noncryogenic synthesis of functionalized 2-methoxypyridines by halogen-magnesium exchange using lithium dibutyl(isopropyl)magnesate(1-) and lithium chloride
    Struk, Lukasz; Sosnicki, Jacek G.
    Synthesis (2012), 44 (5), 735-746CODEN: SYNTBF; ISSN:0039-7881. (Georg Thieme Verlag)
    2-Methoxypyridines functionalized in the 3-, 5-, or 6-position and 2,6-dimethoxypyridines functionalized in the 3-position were prepd. from the corresponding bromo or iodo analogs by using lithium dibutyl(isopropyl)magnesate(1-) and lithium chloride under noncryogenic conditions. The procedure was optimized in terms of the choice between two magnesates and the presence or absence of lithium chloride in the reaction medium.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsFOhsLg%253D&md5=5fd66a1575516dade1ddd9a63de85455
  13. 13
    Das, P.; De Brabander, J. K. A Room Temperature Copper Catalyzed N-Selective Arylation of β-Amino Alcohols with Iodoanilines and Aryl Iodides Tetrahedron 2013, 69, 7646– 7652
    Google Scholar
    There is no corresponding record for this reference.
  14. 14
    Similar observations have been made by the De Brabander group with regard to the work published in ref 13 (De Brabander, J. K. Personal communication).
    Google Scholar
    There is no corresponding record for this reference.

    Recently this work was retracted because of variability of the results with some substrates, although we have reproduced the results in Schemes 1 and 2 on a >2 g scale. See:

    Das, P.; De Brabander, J. K. Retraction Notice to “A Room Temperature Copper Catalyzed N-Selective Arylation of β-Amino Alcohols with Iodoanilines and Aryl Iodides” [Tetrahedron 69 (2013) 7646–7652] Tetrahedron 2014, 70, 1017
    Google Scholar
    There is no corresponding record for this reference.
  15. 15
    Bombrun, A.; Gerber, P.; Casi, G.; Terradillos, O.; Antonsson, B.; Halazy, S. 3,6-Dibromocarbazole Piperazine Derivatives of 2-Propanol as First Inhibitors of Cytochrome C Release Via Bax Channel Modulation J. Med. Chem. 2003, 46, 4365– 4368
    Google Scholar
    There is no corresponding record for this reference.
  16. 16
    Klunder, J. M.; Onami, T.; Sharpless, K. B. Arenesulfonate Derivatives of Homochiral Glycidol: Versatile Chiral Building Blocks for Organic Synthesis J. Org. Chem. 1989, 54, 1295– 1304
    Google Scholar
    16
    Arenesulfonate derivatives of homochiral glycidol: versatile chiral building blocks for organic synthesis
    Klunder, Janice M.; Onami, Tetsuo; Sharpless, K. Barry
    Journal of Organic Chemistry (1989), 54 (6), 1295-304CODEN: JOCEAH; ISSN:0022-3263.
    The prepn. of a series of cryst. arenesulfonate derivs. of enantiomerically enriched glycidol is described. The enhancement of optical purity by recrystn. was particularly successful for two of these derivs., glycidyl tosylate and glycidyl 3-nitrobenzenesulfonate, which were obtained in 97% ee and 99% ee, resp. Very high regioselectivity was obsd. in the reactions of these compds. with a variety of nucleophiles, including aryl oxides, Et2AlCN, organometallic reagents, and BH3-NaBH4. The application of this methodol. to the synthesis of homochiral β-adrenergic blocking agents and homochiral terminal epoxides is discussed.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXhtlCqurc%253D&md5=a7b12df2ca30fa1b1b3f5fdead5d08f0
  17. 17
    Zhao, X.; Zhuang, W.; Fang, D.; Xue, X.; Zhou, J. A Highly Efficient Conversion of Primary or Secondary Alcohols into Fluorides with N-Perfluorobutanesulfonyl Fluoride–Tetrabutylammonium Triphenyldifluorosilicate Synlett 2009, 779– 782
    Google Scholar
    There is no corresponding record for this reference.
  18. 18
    (a) Javitch, J. A.; D’Amato, R. J.; Strittmatter, S. M.; Snyder, S. H. Parkinsonism-Inducing Neurotoxin, N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the Metabolite N-Methyl-4-phenylpyridine by Dopamine Neurons Explains Selective Toxicity Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 2173– 2177
    Google Scholar
    There is no corresponding record for this reference.
    (b) D’Amato, R. J.; Lipman, Z. P.; Snyder, S. H. Selectivity of the Parkinsonian Neurotoxin Mptp: Toxic Metabolite Mpp+ Binds to Neuromelanin Science 1986, 231, 987– 989
    Google Scholar
    There is no corresponding record for this reference.
  19. 19
    Fukuda, T. Neurotoxicity of MPTP Neuropathology 2001, 21, 323– 332
    Google Scholar
    There is no corresponding record for this reference.
  20. 20
    Jackson-Lewis, V.; Przedborski, S. Protocol for the MPTP Mouse Model of Parkinson’s Disease Nat. Protoc. 2007, 2, 141– 151
    Google Scholar
    There is no corresponding record for this reference.
  21. 21
    Wang, C.; Williams, N. S. A Mass Balance Approach for Calculation of Recovery and Binding Enables the Use of Ultrafiltration as a Rapid Method for Measurement of Plasma Protein Binding for Even Highly Lipophilic Compounds J. Pharm. Biomed. Anal. 2013, 75, 112– 117
    Google Scholar
    21
    A mass balance approach for calculation of recovery and binding enables the use of ultrafiltration as a rapid method for measurement of plasma protein binding for even highly lipophilic compounds
    Wang, Changguang; Williams, Noelle S.
    Journal of Pharmaceutical and Biomedical Analysis (2013), 75 (), 112-117CODEN: JPBADA; ISSN:0731-7085. (Elsevier B.V.)
    The aim of this study is to further validate the use of ultrafiltration (UF) as a method for detg. plasma protein binding (PPB) by demonstrating that non-specific binding (NSB) is not a limitation, even for highly lipophilic compds., because NSB sites on the app. are passivated in the presence of plasma. Mass balance theory was used to calc. recovery of 20 com. and seven investigational compds. during ultrafiltration in the presence and absence of plasma. PPB was also measured using this mass balance approach for comparison to PPB detd. by rapid equil. dialysis (RED) and as found in the literature. Compd. recovery during UF was dramatically different in the presence and absence of plasma for compds. with high NSB in PBS only. A comparison of PPB calcd. by ultrafiltration with literature values or calcd. by RED gave concordant results. Discrepancies could be explained by changes in pH, insufficient time to equil., or compd. instability during RED, problems which were circumvented by ultrafiltration. Therefore, NSB, as measured by the traditional incubation of compd. in PBS, need not be an issue when choosing UF as a PPB assay method. It is more appropriate to calc. compd. recovery from the device in plasma as measured by mass balance to det. the suitability of the method for an individual compd. The speed with which UF can be conducted addnl. avoids changes in pH or compd. loss that can occur with other methods. The mass balance approach to UF is thus a preferred method for rapid detn. of PPB.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt1WnsQ%253D%253D&md5=c5d42f85a2cd8edafae32d9662faabed
  22. 22
    Rupprecht, R.; Papadopoulos, V.; Rammes, G.; Baghai, T. C.; Fan, J.; Akula, N.; Groyer, G.; Adams, D.; Schumacher, M. Translocator Protein (18 KDa) (TSPO) as a Therapeutic Target for Neurological and Psychiatric Disorders Nat. Rev. Drug Discovery 2010, 9, 971– 988
    Google Scholar
    22
    Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders
    Rupprecht, Rainer; Papadopoulos, Vassilios; Rammes, Gerhard; Baghai, Thomas C.; Fan, Jinjiang; Akula, Nagaraju; Groyer, Ghislaine; Adams, David; Schumacher, Michael
    Nature Reviews Drug Discovery (2010), 9 (12), 971-988CODEN: NRDDAG; ISSN:1474-1776. (Nature Publishing Group)
    A review. The translocator protein (18 kDa) (TSPO) is localized primarily in the outer mitochondrial membrane of steroid-synthesizing cells, including those in the central and peripheral nervous system. One of its main functions is the transport of the substrate cholesterol into mitochondria, a prerequisite for steroid synthesis. TSPO expression may constitute a biomarker of brain inflammation and reactive gliosis that could be monitored by using TSPO ligands as neuroimaging agents. Moreover, initial clin. trials have indicated that TSPO ligands might be valuable in the treatment of neurol. and psychiatric disorders. This Review focuses on the biol. and pathophysiol. of TSPO and the potential of currently available TSPO ligands for the diagnosis and treatment of neurol. and psychiatric disorders.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsV2ju73E&md5=d2376d74a6ddd0eb795aa34d9e4df3f3
  23. 23
    (a) Bordet, T.; Berna, P.; Abitbol, J.-L.; Pruss, R. M. Olesoxime (Tro19622): A Novel Mitochondrial-Targeted Neuroprotective Compound Pharmaceuticals 2010, 3, 345– 368
    Google Scholar
    There is no corresponding record for this reference.
    (b) Sunyach, C.; Michaud, M.; Arnoux, T.; Bernard-Marissal, N.; Aebischer, J.; Latyszenok, V.; Gouarne, C.; Raoul, C.; Pruss, R. M.; Bordet, T.; Pettmann, B. Olesoxime Delays Muscle Denervation, Astrogliosis, Microglial Activation and Motoneuron Death in an ALS Mouse Model Neuropharmacology 2012, 62, 2346– 2353
    Google Scholar
    There is no corresponding record for this reference.
  24. 24
    Elmkaddem, M. K.; Fischmeister, C.; Thomas, C. M.; Renaud, J.-L. Efficient Synthesis of Aminopyridine Derivatives by Copper Catalyzed Amination Reactions Chem. Commun. 2010, 46, 925– 927
    Google Scholar
    24
    Efficient synthesis of aminopyridine derivatives by copper catalyzed amination reactions
    Elmkaddem, Mohammed K.; Fischmeister, Cedric; Thomas, Christophe M.; Renaud, Jean-Luc
    Chemical Communications (Cambridge, United Kingdom) (2010), 46 (6), 925-927CODEN: CHCOFS; ISSN:1359-7345. (Royal Society of Chemistry)
    A copper(I) catalyzed amination reaction utilizing aq. ammonia and operating under mild conditions is presented. This method was employed for the efficient synthesis of various aminopyridine derivs. bearing electron withdrawing and electron donating groups.
    >> More from SciFinder ®
    https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFOisrg%253D&md5=4a2759fea5464db1ae392168bf0993c7

Cited By

Click to copy section linkSection link copied!

This article is cited by 56 publications.

  1. Alexandre M. Sorlin, Fuad O. Usman, Connor K. English, Hien M. Nguyen. Advances in Nucleophilic Allylic Fluorination. ACS Catalysis 2020, 10 (20) , 11980-12010. https://doi.org/10.1021/acscatal.0c03493
  2. Lin Chen, Jin He. DABCO-Catalyzed Michael/Alkylation Cascade Reactions Involving α-Substituted Ammonium Ylides for the Construction of Spirocyclopropyl Oxindoles: Access to the Powerful Chemical Leads against HIV-1. The Journal of Organic Chemistry 2020, 85 (8) , 5203-5219. https://doi.org/10.1021/acs.joc.9b03164
  3. Elisa Uliassi, Luis Emiliano Peña-Altamira, Aixa V. Morales, Francesca Massenzio, Sabrina Petralla, Michele Rossi, Marinella Roberti, Loreto Martinez Gonzalez, Ana Martinez, Barbara Monti, Maria Laura Bolognesi. A Focused Library of Psychotropic Analogues with Neuroprotective and Neuroregenerative Potential. ACS Chemical Neuroscience 2019, 10 (1) , 279-294. https://doi.org/10.1021/acschemneuro.8b00242
  4. Jason C. Mixdorf, Alexandre M. Sorlin, David W. Dick, Hien M. Nguyen. Iridium-Catalyzed Radiosynthesis of Branched Allylic [18F]Fluorides. Organic Letters 2019, 21 (1) , 60-64. https://doi.org/10.1021/acs.orglett.8b03496
  5. Zhiren Wang, Jinhui Hu, Xiaoping Yang, Xing Feng, Xingshu Li, Ling Huang, Albert S. C. Chan. Design, Synthesis, and Evaluation of Orally Bioavailable Quinoline–Indole Derivatives as Innovative Multitarget-Directed Ligands: Promotion of Cell Proliferation in the Adult Murine Hippocampus for the Treatment of Alzheimer’s Disease. Journal of Medicinal Chemistry 2018, 61 (5) , 1871-1894. https://doi.org/10.1021/acs.jmedchem.7b01417
  6. Jason C. Mixdorf, Alexandre M. Sorlin, Qi Zhang, and Hien M. Nguyen . Asymmetric Synthesis of Allylic Fluorides via Fluorination of Racemic Allylic Trichloroacetimidates Catalyzed by a Chiral Diene-Iridium Complex. ACS Catalysis 2018, 8 (2) , 790-801. https://doi.org/10.1021/acscatal.7b03786
  7. Edward T. Mwenda and Hien M. Nguyen . Enantioselective Synthesis of 1,2-Diamines Containing Tertiary and Quaternary Centers through Rhodium-Catalyzed DYKAT of Racemic Allylic Trichloroacetimidates. Organic Letters 2017, 19 (18) , 4814-4817. https://doi.org/10.1021/acs.orglett.7b02256
  8. Amin Reza Zolghadr and Maryam Heydari Dokoohaki . How Does the P7C3-Series of Neuroprotective Small Molecules Prevent Membrane Disruption?. Journal of Chemical Information and Modeling 2017, 57 (8) , 2009-2019. https://doi.org/10.1021/acs.jcim.7b00151
  9. Colleen M. Connelly, Robert E. Boer, Michelle H. Moon, Peter Gareiss, and John S. Schneekloth, Jr. . Discovery of Inhibitors of MicroRNA-21 Processing Using Small Molecule Microarrays. ACS Chemical Biology 2017, 12 (2) , 435-443. https://doi.org/10.1021/acschembio.6b00945
  10. Chia-Yi Cheng, Chun-Ping Chang, Tsai-Ling Yang Lauderdale, Guann-Yi Yu, Jinq-Chyi Lee, Yi-Wun Jhang, Chien-Huang Wu, Yi-Yu Ke, Amit A. Sadani, Ching-Fang Yeh, I-Wen Huang, Yi-Ping Kuo, De-Jiun Tsai, Teng-Kuang Yeh, Chen-Tso Tseng, Jen-Shin Song, Yu-Wei Liu, Lun K. Tsou, and Kak-Shan Shia . Bromomethylthioindole Inspired Carbazole Hybrids as Promising Class of Anti-MRSA Agents. ACS Medicinal Chemistry Letters 2016, 7 (12) , 1191-1196. https://doi.org/10.1021/acsmedchemlett.6b00289
  11. Pier Alexandre Champagne, Justine Desroches, Jean-Denys Hamel, Mathilde Vandamme, and Jean-François Paquin . Monofluorination of Organic Compounds: 10 Years of Innovation. Chemical Reviews 2015, 115 (17) , 9073-9174. https://doi.org/10.1021/cr500706a
  12. Maciej M. Kucharski, Allan J. B. Watson, Guy C. Lloyd-Jones. Speciation and kinetics of fluoride transfer from tetra- n -butylammonium difluorotriphenylsilicate (‘TBAT’). Chemical Science 2024, 15 (12) , 4331-4340. https://doi.org/10.1039/D3SC05776C
  13. Fei Wen, Gang Gui, Xiaoyu Wang, Li Ye, Anqi Qin, Chen Zhou, Xiaoming Zha. Drug discovery targeting nicotinamide phosphoribosyltransferase (NAMPT): Updated progress and perspectives. Bioorganic & Medicinal Chemistry 2024, 99 , 117595. https://doi.org/10.1016/j.bmc.2024.117595
  14. Preethy S. Sridharan, Emiko Miller, Andrew A. Pieper. Application of P7C3 Compounds to Investigating and Treating Acute and Chronic Traumatic Brain Injury. Neurotherapeutics 2023, 20 (6) , 1616-1628. https://doi.org/10.1007/s13311-023-01427-8
  15. Yong Peng, Hong Jin, Ya-hui Xue, Quan Chen, Shun-yu Yao, Miao-qiao Du, Shu Liu. Current and future therapeutic strategies for Alzheimer’s disease: an overview of drug development bottlenecks. Frontiers in Aging Neuroscience 2023, 15 https://doi.org/10.3389/fnagi.2023.1206572
  16. Ravichandran Manjupriya, Kamalanathan Pouthika, Gunabalan Madhumitha, Selvaraj Mohana Roopan. Biological aspects of nitrogen heterocycles for amyotrophic lateral sclerosis. Applied Microbiology and Biotechnology 2023, 107 (1) , 43-56. https://doi.org/10.1007/s00253-022-12317-y
  17. Wei-Song Xie, Kiran Shehzadi, Hong-Le Ma, Jian-Hua Liang. A Potential Strategy for Treatment of Neurodegenerative Disorders by Regulation of Adult Hippocampal Neurogenesis in Human Brain. Current Medicinal Chemistry 2022, 29 (32) , 5315-5347. https://doi.org/10.2174/0929867329666220509114232
  18. Zhichao Zhong, Xingrui He, Jiamin Ge, Junlong Zhu, Chuansheng Yao, Hong Cai, Xiang-Yang Ye, Tian Xie, Renren Bai. Discovery of small-molecule compounds and natural products against Parkinson's disease: Pathological mechanism and structural modification. European Journal of Medicinal Chemistry 2022, 237 , 114378. https://doi.org/10.1016/j.ejmech.2022.114378
  19. Lucas Alexandre Santos Marzano, Fabyolla Lúcia Macedo de Castro, Caroline Amaral Machado, João Luís Vieira Monteiro de Barros, Thiago Macedo e Cordeiro, Ana Cristina Simões e Silva, Antônio Lúcio Teixeira, Aline Silva de Miranda. Potential Role of Adult Hippocampal Neurogenesis in Traumatic Brain Injury. Current Medicinal Chemistry 2022, 29 (19) , 3392-3419. https://doi.org/10.2174/0929867328666210923143713
  20. Leibo Wang, Minghui Liu, Yumeng Zu, Hong Yao, Chou Wu, Ruoxi Zhang, Weinan Ma, Haigen Lu, Shuang Xi, Yang Liu, Lan Hua, Gelin Wang, Yefeng Tang. Optimization of NAMPT activators to achieve in vivo neuroprotective efficacy. European Journal of Medicinal Chemistry 2022, 236 , 114260. https://doi.org/10.1016/j.ejmech.2022.114260
  21. Samuel Lundt, Shinghua Ding. NAD+ Metabolism and Diseases with Motor Dysfunction. Genes 2021, 12 (11) , 1776. https://doi.org/10.3390/genes12111776
  22. Rachel Schroeder, Preethy Sridharan, Lynn Nguyen, Alexandra Loren, Noelle S. Williams, Kavitha P. Kettimuthu, Coral J. Cintrón-Pérez, Edwin Vázquez-Rosa, Andrew A. Pieper, Hanna E. Stevens. Maternal P7C3-A20 Treatment Protects Offspring from Neuropsychiatric Sequelae of Prenatal Stress. Antioxidants & Redox Signaling 2021, 35 (7) , 511-530. https://doi.org/10.1089/ars.2020.8227
  23. Kaiming Li, Mark F van Delft, Grant Dewson. Too much death can kill you: inhibiting intrinsic apoptosis to treat disease. The EMBO Journal 2021, 40 (14) https://doi.org/10.15252/embj.2020107341
  24. Wenjin Chen, Weiqiang Jia, Cuiying Wu, Lihua Chen, Kai Sun, Ji Wang, Boyun Ding, Ning Liu, Ruxiang Xu. The Neurogenic Compound P7C3 Regulates the Aerobic Glycolysis by Targeting Phosphoglycerate Kinase 1 in Glioma. Frontiers in Oncology 2021, 11 https://doi.org/10.3389/fonc.2021.644492
  25. Dekun Zhang, Yunrong Chen, Yongning Lai, Xiaoyu Yang. Enantioselective desymmetrization of 2-substituted and 2,2-disubstituted 1,3-propanediamines via asymmetric para-aminations of anilines. Cell Reports Physical Science 2021, 2 (5) , 100413. https://doi.org/10.1016/j.xcrp.2021.100413
  26. Sang Wan Ryu, Yeo Ok Kim, Han-Byul Kim, Seog Bae Oh, Jeong Il Choi, Myung Ha Yoon. Antinociceptive effect of intrathecal P7C3 via GABA in a rat model of inflammatory pain. European Journal of Pharmacology 2021, 899 , 174029. https://doi.org/10.1016/j.ejphar.2021.174029
  27. Edwin Vázquez-Rosa, Min-Kyoo Shin, Matasha Dhar, Kalyani Chaubey, Coral J. Cintrón-Pérez, Xinmiao Tang, Xudong Liao, Emiko Miller, Yeojung Koh, Sarah Barker, Kathryn Franke, Danyel R. Crosby, Rachel Schroeder, Josie Emery, Terry C. Yin, Hisashi Fujioka, James D. Reynolds, Matthew M. Harper, Mukesh K. Jain, Andrew A. Pieper. P7C3-A20 treatment one year after TBI in mice repairs the blood–brain barrier, arrests chronic neurodegeneration, and restores cognition. Proceedings of the National Academy of Sciences 2020, 117 (44) , 27667-27675. https://doi.org/10.1073/pnas.2010430117
  28. Nigel S. Simpkins, Frederick E. Nytko, Philip DeShong, Marie Vayer, Nuno Maulide. Tetrabutylammonium Difluorotriphenylsilicate (TBAT). 2020, 1-14. https://doi.org/10.1002/047084289X.rn00469.pub3
  29. Maryam Heydari Dokoohaki, Amin Reza Zolghadr, Axel Klein. Impact of the chemical structure on the distribution of neuroprotective N -alkyl-9 H -carbazoles at octanol/water interfaces. New Journal of Chemistry 2020, 44 (4) , 1211-1220. https://doi.org/10.1039/C9NJ04251B
  30. Fei-Xiang Duan, Yu-Jiao Shi, Jing Chen, Shu-Qin Ding, Feng-Chao Wang, Jie Tang, Rui Wang, Lin Shen, Jin Xi, Qi Qi, He-Zuo Lü, Jian-Guo Hu. Neuroprotective effects of P7C3 against spinal cord injury in rats. Experimental Biology and Medicine 2019, 244 (18) , 1680-1687. https://doi.org/10.1177/1535370219888620
  31. Marianna Tosato, Valerio Di Marco. Metal Chelation Therapy and Parkinson’s Disease: A Critical Review on the Thermodynamics of Complex Formation between Relevant Metal Ions and Promising or Established Drugs. Biomolecules 2019, 9 (7) , 269. https://doi.org/10.3390/biom9070269
  32. Ying Chen, Bolin Wu, Yameng Hao, Yunqi Liu, Zhili Zhang, Chao Tian, Xianling Ning, Ying Guo, Junyi Liu, Xiaowei Wang. Structure-activity relationship studies of (E)-3,4-dihydroxystyryl alkyl sulfones as novel neuroprotective agents based on improved antioxidant, anti-inflammatory activities and BBB permeability. European Journal of Medicinal Chemistry 2019, 171 , 420-433. https://doi.org/10.1016/j.ejmech.2019.03.044
  33. Hedayat Karimi, Maryam Heydari Dokoohaki, Amin Reza Zolghadr, Mohammad Hadi Ghatee. The interactions of an Aβ protofibril with a cholesterol-enriched membrane and involvement of neuroprotective carbazolium-based substances. Physical Chemistry Chemical Physics 2019, 21 (21) , 11066-11078. https://doi.org/10.1039/C9CP00859D
  34. Meghan O. Blaya, Joseph M. Wasserman, Andrew A. Pieper, Thomas J. Sick, Helen M. Bramlett, W. Dalton Dietrich. Neurotherapeutic capacity of P7C3 agents for the treatment of Traumatic Brain Injury. Neuropharmacology 2019, 145 , 268-282. https://doi.org/10.1016/j.neuropharm.2018.09.024
  35. Melissa D. Bauman, Cynthia M. Schumann, Erin L. Carlson, Sandra L. Taylor, Edwin Vázquez-Rosa, Coral J. Cintrón-Pérez, Min-Kyoo Shin, Noelle S. Williams, Andrew A. Pieper. Neuroprotective efficacy of P7C3 compounds in primate hippocampus. Translational Psychiatry 2018, 8 (1) https://doi.org/10.1038/s41398-018-0244-1
  36. Jaymie R. Voorhees, Matthew T. Remy, Coral J. Cintrón-Pérez, Eli El Rassi, Michael Z. Khan, Laura M. Dutca, Terry C. Yin, Latisha N. McDaniel, Noelle S. Williams, Daniel J. Brat, Andrew A. Pieper. (−)-P7C3-S243 Protects a Rat Model of Alzheimer’s Disease From Neuropsychiatric Deficits and Neurodegeneration Without Altering Amyloid Deposition or Reactive Glia. Biological Psychiatry 2018, 84 (7) , 488-498. https://doi.org/10.1016/j.biopsych.2017.10.023
  37. Yea-Hwey Wang, Kuo-Tong Liou, Keng-Chang Tsai, Hui-Kang Liu, Li-Ming Yang, Chang-Ming Chern, Yuh-Chiang Shen. GSK-3 inhibition through GLP-1R allosteric activation mediates the neurogenesis promoting effect of P7C3 after cerebral ischemic/reperfusional injury in mice. Toxicology and Applied Pharmacology 2018, 357 , 88-105. https://doi.org/10.1016/j.taap.2018.08.023
  38. Xiao Zhang, Ying Wang, Sheng-nan Wang, Qiu-he Chen, Ya-lin Tu, Xiao-hong Yang, Jing-kao Chen, Jin-wu Yan, Rong-biao Pi, Yan Wang. Discovery of a novel multifunctional carbazole–aminoquinoline dimer for Alzheimer's disease: copper selective chelation, anti-amyloid aggregation, and neuroprotection. Medicinal Chemistry Research 2018, 27 (3) , 777-784. https://doi.org/10.1007/s00044-017-2101-9
  39. Andrew A. Pieper, Steven L. McKnight. Benefits of Enhancing Nicotinamide Adenine Dinucleotide Levels in Damaged or Diseased Nerve Cells. Cold Spring Harbor Symposia on Quantitative Biology 2018, 83 , 207-217. https://doi.org/10.1101/sqb.2018.83.037622
  40. Jian-Hua Liang, Liang Yang, Si Wu, Si-Si Liu, Mark Cushman, Jing Tian, Nuo-Min Li, Qing-Hu Yang, He-Ao Zhang, Yun-Jie Qiu, Lin Xiang, Cong-Xuan Ma, Xue-Meng Li, Hong Qing. Discovery of efficient stimulators for adult hippocampal neurogenesis based on scaffolds in dragon's blood. European Journal of Medicinal Chemistry 2017, 136 , 382-392. https://doi.org/10.1016/j.ejmech.2017.05.025
  41. Zeeba D. Kabir, Arlene Martínez-Rivera, Anjali M. Rajadhyaksha. From Gene to Behavior: L-Type Calcium Channel Mechanisms Underlying Neuropsychiatric Symptoms. Neurotherapeutics 2017, 14 (3) , 588-613. https://doi.org/10.1007/s13311-017-0532-0
  42. Elisa Uliassi, Annachiara Gandini, Rosaria Carmela Perone, Maria Laura Bolognesi. Neuroregeneration Versus Neurodegeneration: Toward a Paradigm Shift in Alzheimer'S Disease Drug Discovery. Future Medicinal Chemistry 2017, 9 (10) , 995-1013. https://doi.org/10.4155/fmc-2017-0038
  43. Zachary B. Loris, Andrew A. Pieper, W. Dalton Dietrich. The neuroprotective compound P7C3-A20 promotes neurogenesis and improves cognitive function after ischemic stroke. Experimental Neurology 2017, 290 , 63-73. https://doi.org/10.1016/j.expneurol.2017.01.006
  44. Joong Hyun Shim. Anti-aging Effects of P7C3 in UVA-irradiated Human Dermal Fibroblasts. Asian Journal of Beauty and Cosmetology 2017, 15 (1) , 45-53. https://doi.org/10.20402/ajbc.2016.0094
  45. Pablo M. Peixoto, Oscar Teijido, Oygul Mirzalieva, Laurent M. Dejean, Evgeny V. Pavlov, Bruno Antonsson, Kathleen W. Kinnally. MAC inhibitors antagonize the pro-apoptotic effects of tBid and disassemble Bax / Bak oligomers. Journal of Bioenergetics and Biomembranes 2017, 49 (1) , 65-74. https://doi.org/10.1007/s10863-015-9635-7
  46. Songbo Lin, Xingrui He, Jinpeng Meng, Haining Gu, Peizhi Zhang, Jun Wu. An Expedient Synthesis of Carbazoles through Potassium tert ‐Butoxide‐Promoted Intramolecular Direct C–H Bond Arylation. European Journal of Organic Chemistry 2017, 2017 (3) , 443-447. https://doi.org/10.1002/ejoc.201601293
  47. Terry C. Yin, Jaymie R. Voorhees, Rachel M. Genova, Kevin C. Davis, Ashley M. Madison, Jeremiah K. Britt, Coral J. Cintrón-Pérez, Latisha McDaniel, Matthew M. Harper, Andrew A. Pieper. Acute Axonal Degeneration Drives Development of Cognitive, Motor, and Visual Deficits after Blast-Mediated Traumatic Brain Injury in Mice. eneuro 2016, 3 (5) , ENEURO.0220-16.2016. https://doi.org/10.1523/ENEURO.0220-16.2016
  48. Shu‐Na Wang, Tian‐Ying Xu, Xia Wang, Yun‐Feng Guan, Sai‐Long Zhang, Pei Wang, Chao‐Yu Miao. Neuroprotective Efficacy of an Aminopropyl Carbazole Derivative P7C3‐A20 in Ischemic Stroke. CNS Neuroscience & Therapeutics 2016, 22 (9) , 782-788. https://doi.org/10.1111/cns.12576
  49. Shu‐Na Wang, Tian‐Ying Xu, Wen‐Lin Li, Chao‐Yu Miao. Targeting Nicotinamide Phosphoribosyltransferase as a Potential Therapeutic Strategy to Restore Adult Neurogenesis. CNS Neuroscience & Therapeutics 2016, 22 (6) , 431-439. https://doi.org/10.1111/cns.12539
  50. Anni S. Lee, Héctor De Jesús-Cortés, Zeeba D. Kabir, Whitney Knobbe, Madeline Orr, Caitlin Burgdorf, Paula Huntington, Latisha McDaniel, Jeremiah K. Britt, Franz Hoffmann, Daniel J. Brat, Anjali M. Rajadhyaksha, Andrew A. Pieper. The Neuropsychiatric Disease-Associated Gene cacna1c Mediates Survival of Young Hippocampal Neurons. eneuro 2016, 3 (2) , ENEURO.0006-16.2016. https://doi.org/10.1523/ENEURO.0006-16.2016
  51. Héctor De Jesús-Cortés, Anjali M. Rajadhyaksha, Andrew A. Pieper. Cacna1c: Protecting young hippocampal neurons in the adult brain. Neurogenesis 2016, 3 (1) , e1231160. https://doi.org/10.1080/23262133.2016.1231160
  52. Héctor De Jesús-Cortés, Adam D Miller, Jeremiah K Britt, Anthony J DeMarco, Mayralis De Jesús-Cortés, Emily Stuebing, Jacinth Naidoo, Edwin Vázquez-Rosa, Lorraine Morlock, Noelle S Williams, Joseph M Ready, Nandakumar S Narayanan, Andrew A Pieper. Protective efficacy of P7C3-S243 in the 6-hydroxydopamine model of Parkinson's disease. npj Parkinson's Disease 2015, 1 (1) https://doi.org/10.1038/npjparkd.2015.10
  53. S.W.P. Kemp, M. Szynkaruk, K.N. Stanoulis, M.D. Wood, E.H. Liu, M.P. Willand, L. Morlock, J. Naidoo, N.S. Williams, J.M. Ready, T.J. Mangano, S. Beggs, M.W. Salter, T. Gordon, A.A. Pieper, G.H. Borschel. Pharmacologic rescue of motor and sensory function by the neuroprotective compound P7C3 following neonatal nerve injury. Neuroscience 2015, 284 , 202-216. https://doi.org/10.1016/j.neuroscience.2014.10.005
  54. C. Thiehoff, M. C. Holland, C. Daniliuc, K. N. Houk, R. Gilmour. Can acyclic conformational control be achieved via a sulfur–fluorine gauche effect?. Chemical Science 2015, 6 (6) , 3565-3571. https://doi.org/10.1039/C5SC00871A
  55. Gelin Wang, Ting Han, Deepak Nijhawan, Pano Theodoropoulos, Jacinth Naidoo, Sivaramakrishnan Yadavalli, Hamid Mirzaei, Andrew A. Pieper, Joseph M. Ready, Steven L. McKnight. P7C3 Neuroprotective Chemicals Function by Activating the Rate-Limiting Enzyme in NAD Salvage. Cell 2014, 158 (6) , 1324-1334. https://doi.org/10.1016/j.cell.2014.07.040
  56. Terry C. Yin, Jeremiah K. Britt, Héctor De Jesús-Cortés, Yuan Lu, Rachel M. Genova, Michael Z. Khan, Jaymie R. Voorhees, Jianqiang Shao, Aaron C. Katzman, Paula J. Huntington, Cassie Wassink, Latisha McDaniel, Elizabeth A. Newell, Laura M. Dutca, Jacinth Naidoo, Huxing Cui, Alexander G. Bassuk, Matthew M. Harper, Steven L. McKnight, Joseph M. Ready, Andrew A. Pieper. P7C3 Neuroprotective Chemicals Block Axonal Degeneration and Preserve Function after Traumatic Brain Injury. Cell Reports 2014, 8 (6) , 1731-1740. https://doi.org/10.1016/j.celrep.2014.08.030
Download PDF
Open PDF
Go to Journal of Medicinal Chemistry
Get e-Alerts
Get e-Alerts

Journal of Medicinal Chemistry

Cite this: J. Med. Chem. 2014, 57, 9, 3746–3754
Click to copy citationCitation copied!
https://doi.org/10.1021/jm401919s
Published April 3, 2014

Copyright © 2014 American Chemical Society. This publication is licensed under these Terms of Use.

Request reuse permissions

Article Views

4247

Altmetric

-

Citations

56
Learn about these metrics

Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.

Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.

The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated.

  • Abstract

    High Resolution Image
    Download MS PowerPoint Slide

    Scheme 1

    High Resolution Image
    Download MS PowerPoint Slide

    Figure 1

    Figure 1. Efficacy of 15 in a mouse model of neurogenesis. Compounds were administered using the indicated dose and method for 7 days, during which time mice were dosed IP daily with BrdU (50 mg kg–1 day–1) to label newborn hippocampal neurons. Data are shown as mean ± standard error of the mean (SEM).

    High Resolution Image
    Download MS PowerPoint Slide

    Scheme 2

    Scheme 2. Stereoselective Synthesis of (−)-15
    High Resolution Image
    Download MS PowerPoint Slide

    Figure 2

    Figure 2. Enantiomer-specific efficacy of 15 in a mouse model of neurogenesis. Compound was administered ICV at the indicated concentration (0.5 μL/h) for 7 days, during which time mice were dosed IP daily with BrdU (50 mg kg–1 day–1) to label newborn hippocampal neurons. The graph shows the mean ± SEM for each group (N = 4 or 5). Images are of representative stained sections. Scale bars = 0.3 mm.

    High Resolution Image
    Download MS PowerPoint Slide

    Figure 3

    Figure 3. Efficacy of 15 in the MPTP model of Parkinson’s disease. Mice were administered MPTP (30 mg kg–1 day–1) for 5 days. On the sixth day, treatment with drug was initiated at the indicated dose (IP, BID, 21 days) . Bars indicate numbers of tyrosine hydroxylase-positive (TH+) cells detected by immunohistochemical staining of the substantia nigra (mean ± SEM). Asterisks indicate p < 0.01 (*), p < 0.001 (**), or p < 0.0001 (***) relative to the vehicle (Veh) + MPTP group. The number of mice in each group is shown within the corresponding bar. Representative immunohistochemical pictures of TH staining in the SNc are shown for 5 mg kg–1 day–1 treatment groups. Scale bars = 300 μM.

    High Resolution Image
    Download MS PowerPoint Slide

  • References

    This article references 24 other publications.

    1. 1
      (a) Lees, A. J.; Hardy, J.; Revesz, T. Parkinson’s Disease Lancet 2009, 373, 2055– 2066
      1a
      Parkinson's disease
      Lees, Andrew J.; Hardy, John; Revesz, Tamas
      Lancet (2009), 373 (9680), 2055-2066CODEN: LANCAO; ISSN:0140-6736. (Elsevier Ltd.)
      A review. Summary: Parkinson's disease is a common progressive bradykinetic disorder that can be accurately diagnosed. It is characterised by the presence of severe pars-compacta nigral-cell loss, and accumulation of aggregated α-synuclein in specific brain stem, spinal cord, and cortical regions. The main known risk factor is age. Susceptibility genes including α-synuclein, leucine rich repeat kinase 2 (LRRK-2), and glucocerebrosidase (GBA) have shown that genetic predisposition is another important causal factor. Dopamine replacement therapy considerably reduces motor handicap, and effective treatment of assocd. depression, pain, constipation, and nocturnal difficulties can improve quality of life. Embryonic stem cells and gene therapy are promising research therapeutic approaches.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnt1ans7w%253D&md5=ae632b0ac91f4e5ee017bf2bf21f5926
      (b) Hebert, L. E.; Scherr, P. A.; Bienias, J. L.; Bennett, D. A.; Evans, D. A. State-Specific Projections through 2025 of Alzheimer Disease Prevalence Neurology 2004, 62, 1645
      There is no corresponding record for this reference.
    2. 2
      (a) Pieper, A. A.; Xie, S.; Capota, E.; Estill, S. J.; Zhong, J.; Long, J. M.; Becker, G. L.; Huntington, P.; Goldman, S. E.; Shen, C.-H.; Capota, M.; Britt, J. K.; Kotti, T.; Ure, K.; Brat, D. J.; Williams, N. S.; MacMillan, K. S.; Naidoo, J.; Melito, L.; Hsieh, J.; De Brabander, J.; Ready, J. M.; McKnight, S. L. Discovery of a Proneurogenic, Neuroprotective Chemical Cell 2010, 142, 39– 51
      2a
      Discovery of a proneurogenic, neuroprotective chemical
      Pieper, Andrew A.; Xie, Shanhai; Capota, Emanuela; Estill, Sandi Jo; Zhong, Jeannie; Long, Jeffrey M.; Becker, Ginger L.; Huntington, Paula; Goldman, Shauna E.; Shen, Ching-Han; Capota, Maria; Britt, Jeremiah K.; Kotti, Tiina; Ure, Kerstin; Brat, Daniel J.; Williams, Noelle S.; MacMillan, Karen S.; Naidoo, Jacinth; Melito, Lisa; Hsieh, Jenny; De Brabander, Jef; Ready, Joseph M.; McKnight, Steven L.
      Cell (Cambridge, MA, United States) (2010), 142 (1), 39-51CODEN: CELLB5; ISSN:0092-8674. (Cell Press)
      An in vivo screen was performed in search of chems. capable of enhancing neuron formation in the hippocampus of adult mice. Eight of 1000 small mols. tested enhanced neuron formation in the subgranular zone of the dentate gyrus. Among these was an aminopropyl carbazole, designated P7C3, endowed with favorable pharmacol. properties. In vivo studies gave evidence that P7C3 exerts its proneurogenic activity by protecting newborn neurons from apoptosis. Mice missing the gene encoding neuronal PAS domain protein 3 (NPAS3) are devoid of hippocampal neurogenesis and display malformation and electrophysiol. dysfunction of the dentate gyrus. Prolonged administration of P7C3 to npas3-/- mice cor. these deficits by normalizing levels of apoptosis of newborn hippocampal neurons. Prolonged administration of P7C3 to aged rats also enhanced neurogenesis in the dentate gyrus, impeded neuron death, and preserved cognitive capacity as a function of terminal aging.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1Cjt7Y%253D&md5=7ed01874bd3e1b5cde587b2bc244741d
      (b) McKnight, S. L.; Pieper, A. A.; Ready, J. M.; De Brabander, J. Proneurogenic Compounds. U.S. Patent 8,604,074, 2013.
      There is no corresponding record for this reference.
      (c) McKnight, S. L.; Pieper, A. A.; Ready, J. M.; De Brabander, J. Proneurogenic Compounds. U.S. Patent 8,362,277, 2013.
      There is no corresponding record for this reference.
    3. 3
      MacMillan, K. S.; Naidoo, J.; Liang, J.; Melito, L.; Williams, N. S.; Morlock, L.; Huntington, P. J.; Estill, S. J.; Longgood, J.; Becker, G. L.; McKnight, S. L.; Pieper, A. A.; De Brabander, J. K.; Ready, J. M. Development of Proneurogenic, Neuroprotective Small Molecules J. Am. Chem. Soc. 2011, 133, 1428– 1437
      There is no corresponding record for this reference.
    4. 4
      Naidoo, J.; Bemben, C. J.; Allwein, S. R.; Liang, J.; Pieper, A. A.; Ready, J. M. Development of a Scalable Synthesis of P7C3-A20, a Potent Neuroprotective Agent Tetrahedron Lett. 2013, 54, 4429– 4431
      There is no corresponding record for this reference.
    5. 5
      De Jesus-Cortes, H.; Xu, P.; Drawbridge, J.; Estill, S. J.; Huntington, P.; Tran, S.; Britt, J.; Tesla, R.; Morlock, L.; Naidoo, J.; Melito, L. M.; Wang, G.; Williams, N. S.; Ready, J. M.; McKnight, S. L.; Pieper, A. A. Neuroprotective Efficacy of Aminopropyl Carbazoles in a Mouse Model of Parkinson Disease Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 17010– 17015
      There is no corresponding record for this reference.
    6. 6
      Tesla, R.; Wolf, H. P.; Xu, P.; Drawbridge, J.; Estill, S. J.; Huntington, P.; McDaniel, L.; Knobbe, W.; Burket, A.; Tran, S.; Starwalt, R.; Morlock, L.; Naidoo, J.; Williams, N. S.; Ready, J. M.; McKnight, S. L.; Pieper, A. A. Neuroprotective Efficacy of Aminopropyl Carbazoles in a Mouse Model of Amyotrophic Lateral Sclerosis Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 17016– 17021
      There is no corresponding record for this reference.
    7. 7
      Blaya, M. O.; Bramlett, H.; Nadoo, J.; Pieper, A. A.; Dietrich, W. D., III. Neuroprotective Efficacy of a Proneurogenic Compound after Traumatic Brain Injury J. Neurotrauma 2014, 31, 476– 468
      7
      Neuroprotective efficacy of a proneurogenic compound after traumatic brain injury
      Blaya Meghan O; Bramlett Helen M; Naidoo Jacinth; Pieper Andrew A; Dietrich W Dalton
      Journal of neurotrauma (2014), 31 (5), 476-86 ISSN:.
      Traumatic brain injury (TBI) is characterized by histopathological damage and long-term sensorimotor and cognitive dysfunction. Recent studies have reported the discovery of the P7C3 class of aminopropyl carbazole agents with potent neuroprotective properties for both newborn neural precursor cells in the adult hippocampus and mature neurons in other regions of the central nervous system. This study tested, for the first time, whether the highly active P7C3-A20 compound would be neuroprotective, promote hippocampal neurogenesis, and improve functional outcomes after experimental TBI. Sprague-Dawley rats subjected to moderate fluid percussion brain injury were evaluated for quantitative immunohistochemical and behavioral changes after trauma. P7C3-A20 (10 mg/kg) or vehicle was initiated intraperitoneally 30 min postsurgery and twice per day every day thereafter for 7 days. Administration of P7C3-A20 significantly reduced overall contusion volume, preserved vulnerable anti-neuronal nuclei (NeuN)-positive pericontusional cortical neurons, and improved sensorimotor function 1 week after trauma. P7C3-A20 treatment also significantly increased both bromodeoxyuridine (BrdU)- and doublecortin (DCX)-positive cells within the subgranular zone of the ipsilateral dentate gyrus 1 week after TBI. Five weeks after TBI, animals treated with P7C3-A20 showed significantly increased BrdU/NeuN double-labeled neurons and improved cognitive function in the Morris water maze, compared to TBI-control animals. These results suggest that P7C3-A20 is neuroprotective and promotes endogenous reparative strategies after TBI. We propose that the chemical scaffold represented by P7C3-A20 provides a basis for optimizing and advancing new pharmacological agents for protecting patients against the early and chronic consequences of TBI.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FhsFyltA%253D%253D&md5=b0b1e5150d33d05dfbf444d86bc16951
    8. 8
      Walker, A. K.; Rivera, P. D.; Wang, Q.; Chuang, J.-C.; Tran, S.; Osborne-Lawrence, S.; Estill, S. J.; Starwalt, R.; Huntington, P.; Morlock, L.; Naidoo, J.; Williams, N.; Ready, J. M.; Eisch, A. J.; Pieper, A. A.; Zigman, J. M. The P7C3-class of Neuroprotective Compounds Exerts Antidepressant Efficacy in Mice by Increasing Hippocampal Neurogenesis. Mol. Psychiatry 2014, in press
      There is no corresponding record for this reference.
    9. 9
      Asai-Coakwell, M.; March, L.; Dai, X. H.; DuVal, M.; Lopez, I.; French, C. R.; Famulski, J.; De Baere, E.; Francis, P. J.; Sundaresan, P.; Sauve, Y.; Koenekoop, R. K.; Berry, F. B.; Allison, W. T.; Waskiewicz, A. J.; Lehmann, O. J. Contribution of Growth Differentiation Factor 6-Dependent Cell Survival to Early-Onset Retinal Dystrophies Hum. Mol. Genet. 2013, 22, 1432– 1442
      9
      Contribution of growth differentiation factor 6-dependent cell survival to early-onset retinal dystrophies
      Asai-Coakwell, Mika; March, Lindsey; Dai, Xiao Hua; DuVal, Michele; Lopez, Irma; French, Curtis R.; Famulski, Jakub; De Baere, Elfride; Francis, Peter J.; Sundaresan, Periasamy; Sauve, Yves; Koenekoop, Robert K.; Berry, Fred B.; Allison, W. Ted; Waskiewicz, Andrew J.; Lehmann, Ordan J.
      Human Molecular Genetics (2013), 22 (7), 1432-1442CODEN: HMGEE5; ISSN:0964-6906. (Oxford University Press)
      Retinal dystrophies are predominantly caused by mutations affecting the visual phototransduction system and cilia, with few genes identified that function to maintain photoreceptor survival. The authors reasoned that growth factors involved with early embryonic retinal development would represent excellent candidates for such diseases. Here they show that mutations in the transforming growth factor-β (TGF-β) ligand Growth Differentiation Factor 6, which specifies the dorso-ventral retinal axis, contribute to Leber congenital amaurosis. Furthermore, deficiency of gdf6 results in photoreceptor degeneration, so demonstrating a connection between Gdf6 signaling and photoreceptor survival. In addn., in both murine and zebrafish mutant models, the authors observe retinal apoptosis, a characteristic feature of human retinal dystrophies. Treatment of gdf6-deficient zebrafish embryos with a novel aminopropyl carbazole, P7C3, rescued the retinal apoptosis without evidence of toxicity. These findings implicate for the first time perturbed TGF-β signaling in the genesis of retinal dystrophies, support the study of related morphogenetic genes for comparable roles in retinal disease and may offer addnl. therapeutic opportunities for genetically heterogeneous disorders presently only treatable with gene therapy.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktV2qu74%253D&md5=1b2b830f91e132831bba5ab9628f19a5
    10. 10

      Mice housed alone and without objects such as nesting material show decreased hippocampal neurogenesis, magnifying the effect of neuroprotective compounds.

      There is no corresponding record for this reference.
    11. 11

      Rough calculations suggested that the test compounds would reach a concentration of approximately 100 nM by the end of the testing period if all of the material remained in the brain.

      There is no corresponding record for this reference.
    12. 12
      Struk, L.; Sosnicki, J. G. Noncryogenic Synthesis of Functionalized 2-Methoxypyridines by Halogen–Magnesium Exchange Using Lithium Dibutyl(Isopropyl)Magnesate and Lithium Chloride Synthesis 2012, 44, 735– 746
      12
      Noncryogenic synthesis of functionalized 2-methoxypyridines by halogen-magnesium exchange using lithium dibutyl(isopropyl)magnesate(1-) and lithium chloride
      Struk, Lukasz; Sosnicki, Jacek G.
      Synthesis (2012), 44 (5), 735-746CODEN: SYNTBF; ISSN:0039-7881. (Georg Thieme Verlag)
      2-Methoxypyridines functionalized in the 3-, 5-, or 6-position and 2,6-dimethoxypyridines functionalized in the 3-position were prepd. from the corresponding bromo or iodo analogs by using lithium dibutyl(isopropyl)magnesate(1-) and lithium chloride under noncryogenic conditions. The procedure was optimized in terms of the choice between two magnesates and the presence or absence of lithium chloride in the reaction medium.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsFOhsLg%253D&md5=5fd66a1575516dade1ddd9a63de85455
    13. 13
      Das, P.; De Brabander, J. K. A Room Temperature Copper Catalyzed N-Selective Arylation of β-Amino Alcohols with Iodoanilines and Aryl Iodides Tetrahedron 2013, 69, 7646– 7652
      There is no corresponding record for this reference.
    14. 14
      Similar observations have been made by the De Brabander group with regard to the work published in ref 13 (De Brabander, J. K. Personal communication).
      There is no corresponding record for this reference.

      Recently this work was retracted because of variability of the results with some substrates, although we have reproduced the results in Schemes 1 and 2 on a >2 g scale. See:

      Das, P.; De Brabander, J. K. Retraction Notice to “A Room Temperature Copper Catalyzed N-Selective Arylation of β-Amino Alcohols with Iodoanilines and Aryl Iodides” [Tetrahedron 69 (2013) 7646–7652] Tetrahedron 2014, 70, 1017
      There is no corresponding record for this reference.
    15. 15
      Bombrun, A.; Gerber, P.; Casi, G.; Terradillos, O.; Antonsson, B.; Halazy, S. 3,6-Dibromocarbazole Piperazine Derivatives of 2-Propanol as First Inhibitors of Cytochrome C Release Via Bax Channel Modulation J. Med. Chem. 2003, 46, 4365– 4368
      There is no corresponding record for this reference.
    16. 16
      Klunder, J. M.; Onami, T.; Sharpless, K. B. Arenesulfonate Derivatives of Homochiral Glycidol: Versatile Chiral Building Blocks for Organic Synthesis J. Org. Chem. 1989, 54, 1295– 1304
      16
      Arenesulfonate derivatives of homochiral glycidol: versatile chiral building blocks for organic synthesis
      Klunder, Janice M.; Onami, Tetsuo; Sharpless, K. Barry
      Journal of Organic Chemistry (1989), 54 (6), 1295-304CODEN: JOCEAH; ISSN:0022-3263.
      The prepn. of a series of cryst. arenesulfonate derivs. of enantiomerically enriched glycidol is described. The enhancement of optical purity by recrystn. was particularly successful for two of these derivs., glycidyl tosylate and glycidyl 3-nitrobenzenesulfonate, which were obtained in 97% ee and 99% ee, resp. Very high regioselectivity was obsd. in the reactions of these compds. with a variety of nucleophiles, including aryl oxides, Et2AlCN, organometallic reagents, and BH3-NaBH4. The application of this methodol. to the synthesis of homochiral β-adrenergic blocking agents and homochiral terminal epoxides is discussed.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXhtlCqurc%253D&md5=a7b12df2ca30fa1b1b3f5fdead5d08f0
    17. 17
      Zhao, X.; Zhuang, W.; Fang, D.; Xue, X.; Zhou, J. A Highly Efficient Conversion of Primary or Secondary Alcohols into Fluorides with N-Perfluorobutanesulfonyl Fluoride–Tetrabutylammonium Triphenyldifluorosilicate Synlett 2009, 779– 782
      There is no corresponding record for this reference.
    18. 18
      (a) Javitch, J. A.; D’Amato, R. J.; Strittmatter, S. M.; Snyder, S. H. Parkinsonism-Inducing Neurotoxin, N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the Metabolite N-Methyl-4-phenylpyridine by Dopamine Neurons Explains Selective Toxicity Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 2173– 2177
      There is no corresponding record for this reference.
      (b) D’Amato, R. J.; Lipman, Z. P.; Snyder, S. H. Selectivity of the Parkinsonian Neurotoxin Mptp: Toxic Metabolite Mpp+ Binds to Neuromelanin Science 1986, 231, 987– 989
      There is no corresponding record for this reference.
    19. 19
      Fukuda, T. Neurotoxicity of MPTP Neuropathology 2001, 21, 323– 332
      There is no corresponding record for this reference.
    20. 20
      Jackson-Lewis, V.; Przedborski, S. Protocol for the MPTP Mouse Model of Parkinson’s Disease Nat. Protoc. 2007, 2, 141– 151
      There is no corresponding record for this reference.
    21. 21
      Wang, C.; Williams, N. S. A Mass Balance Approach for Calculation of Recovery and Binding Enables the Use of Ultrafiltration as a Rapid Method for Measurement of Plasma Protein Binding for Even Highly Lipophilic Compounds J. Pharm. Biomed. Anal. 2013, 75, 112– 117
      21
      A mass balance approach for calculation of recovery and binding enables the use of ultrafiltration as a rapid method for measurement of plasma protein binding for even highly lipophilic compounds
      Wang, Changguang; Williams, Noelle S.
      Journal of Pharmaceutical and Biomedical Analysis (2013), 75 (), 112-117CODEN: JPBADA; ISSN:0731-7085. (Elsevier B.V.)
      The aim of this study is to further validate the use of ultrafiltration (UF) as a method for detg. plasma protein binding (PPB) by demonstrating that non-specific binding (NSB) is not a limitation, even for highly lipophilic compds., because NSB sites on the app. are passivated in the presence of plasma. Mass balance theory was used to calc. recovery of 20 com. and seven investigational compds. during ultrafiltration in the presence and absence of plasma. PPB was also measured using this mass balance approach for comparison to PPB detd. by rapid equil. dialysis (RED) and as found in the literature. Compd. recovery during UF was dramatically different in the presence and absence of plasma for compds. with high NSB in PBS only. A comparison of PPB calcd. by ultrafiltration with literature values or calcd. by RED gave concordant results. Discrepancies could be explained by changes in pH, insufficient time to equil., or compd. instability during RED, problems which were circumvented by ultrafiltration. Therefore, NSB, as measured by the traditional incubation of compd. in PBS, need not be an issue when choosing UF as a PPB assay method. It is more appropriate to calc. compd. recovery from the device in plasma as measured by mass balance to det. the suitability of the method for an individual compd. The speed with which UF can be conducted addnl. avoids changes in pH or compd. loss that can occur with other methods. The mass balance approach to UF is thus a preferred method for rapid detn. of PPB.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt1WnsQ%253D%253D&md5=c5d42f85a2cd8edafae32d9662faabed
    22. 22
      Rupprecht, R.; Papadopoulos, V.; Rammes, G.; Baghai, T. C.; Fan, J.; Akula, N.; Groyer, G.; Adams, D.; Schumacher, M. Translocator Protein (18 KDa) (TSPO) as a Therapeutic Target for Neurological and Psychiatric Disorders Nat. Rev. Drug Discovery 2010, 9, 971– 988
      22
      Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders
      Rupprecht, Rainer; Papadopoulos, Vassilios; Rammes, Gerhard; Baghai, Thomas C.; Fan, Jinjiang; Akula, Nagaraju; Groyer, Ghislaine; Adams, David; Schumacher, Michael
      Nature Reviews Drug Discovery (2010), 9 (12), 971-988CODEN: NRDDAG; ISSN:1474-1776. (Nature Publishing Group)
      A review. The translocator protein (18 kDa) (TSPO) is localized primarily in the outer mitochondrial membrane of steroid-synthesizing cells, including those in the central and peripheral nervous system. One of its main functions is the transport of the substrate cholesterol into mitochondria, a prerequisite for steroid synthesis. TSPO expression may constitute a biomarker of brain inflammation and reactive gliosis that could be monitored by using TSPO ligands as neuroimaging agents. Moreover, initial clin. trials have indicated that TSPO ligands might be valuable in the treatment of neurol. and psychiatric disorders. This Review focuses on the biol. and pathophysiol. of TSPO and the potential of currently available TSPO ligands for the diagnosis and treatment of neurol. and psychiatric disorders.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsV2ju73E&md5=d2376d74a6ddd0eb795aa34d9e4df3f3
    23. 23
      (a) Bordet, T.; Berna, P.; Abitbol, J.-L.; Pruss, R. M. Olesoxime (Tro19622): A Novel Mitochondrial-Targeted Neuroprotective Compound Pharmaceuticals 2010, 3, 345– 368
      There is no corresponding record for this reference.
      (b) Sunyach, C.; Michaud, M.; Arnoux, T.; Bernard-Marissal, N.; Aebischer, J.; Latyszenok, V.; Gouarne, C.; Raoul, C.; Pruss, R. M.; Bordet, T.; Pettmann, B. Olesoxime Delays Muscle Denervation, Astrogliosis, Microglial Activation and Motoneuron Death in an ALS Mouse Model Neuropharmacology 2012, 62, 2346– 2353
      There is no corresponding record for this reference.
    24. 24
      Elmkaddem, M. K.; Fischmeister, C.; Thomas, C. M.; Renaud, J.-L. Efficient Synthesis of Aminopyridine Derivatives by Copper Catalyzed Amination Reactions Chem. Commun. 2010, 46, 925– 927
      24
      Efficient synthesis of aminopyridine derivatives by copper catalyzed amination reactions
      Elmkaddem, Mohammed K.; Fischmeister, Cedric; Thomas, Christophe M.; Renaud, Jean-Luc
      Chemical Communications (Cambridge, United Kingdom) (2010), 46 (6), 925-927CODEN: CHCOFS; ISSN:1359-7345. (Royal Society of Chemistry)
      A copper(I) catalyzed amination reaction utilizing aq. ammonia and operating under mild conditions is presented. This method was employed for the efficient synthesis of various aminopyridine derivs. bearing electron withdrawing and electron donating groups.
      >> More from SciFinder ®
      https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFOisrg%253D&md5=4a2759fea5464db1ae392168bf0993c7

  • Supporting Information

    Supporting Information

    Table of screening results from the Psychoactive Drug Screening Program, X-ray crystal structure of (−)-15, comparison of plasma and brain levels for rac-15 and (−)-15, and spectra of synthetic materials. This material is available free of charge via the Internet at http://pubs.acs.org.


    Terms & Conditions

    Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: http://pubs.acs.org/page/copyright/permissions.html.